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Polyomaviruses can induce tumors in animals and transformation of cells in culture by 
expression of the viral T antigen proteins. The most widely studied polyomavirus, SV40, 
expresses the large T antigen protein (LT), which interacts with many cellular proteins to 
transform cells. Several other polyomaviruses also express a LT protein that is required for 
transformation; however, previous research has hinted that these polyomavirus LTs may not 
transform cells by the same mechanisms. The aim of this work is to uncover the differences in 
molecular mechanisms of transformation by LTs of two human polyomaviruses, BKV and JCV, 
and a primate polyomavirus, LPV, as compared to SV40 LT.  
The LT proteins contain discrete structural domains that are also associated with different 
functions of the protein. These domains can be removed to isolate individual functions without 
greatly altering those functions. Expression of a short fragment of the LT antigens known to 
interact with the cell cycle regulating family of pRB proteins showed that this region confers the 
same transformation capabilities between the four polyomaviruses. The BKV and JCV 
fragments, however, also conferred a growth advantage in the dense focus assay, suggesting 
additional activities of this region of BKV and JCV LT other than pRB inhibition. In a separate 
line of investigation, a region of LT that is only present in SV40, BKV, and JCV LTs known as 
the variable linker and host range region (VHR) was removed. Very little is known about how 
this region of LT effects transformation. Transformation assessed by growth in low serum was 
reduced by VHR truncation of the SV40, but not the JCV, LT. Conversely, anchorage 
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independent transformation was enhanced only by truncation of the JCV VHR. This is the first 
report to link the SV40 or JCV VHR region to transformation potential. Expression of the both 
VHR LT truncations resulted in changes in T antigen expression and cellular p53 post-
translational modifications but interaction with the pRB pathway was unaffected. Future studies 
will focus on identifying the cellular protein interactions with each LT domain that contribute to 
the differences in transformation identified here.  
 vi 
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1.0  INTRODUCTION 
Polyomaviruses (PyV) are part of a group of viruses known as DNA tumor viruses. Tumor 
viruses can induce cancer in their natural hosts or in experimental animal systems. To date, all of 
the mammalian PyVs that have been tested, a total of 8, have this property. Some only induce 
tumors in non-host animal models, while others can induce tumors in the native host and animal 
models. In humans, only one PyV has been shown to be a causative agent of cancer, others can 
cause diseases in immunocompromised patients that are un-related to cancer, while most of the 
discovered human PyVs have no known role in disease. The viral proteins that are responsible 
for tumor formation are also critical for other diseases induced by PyVs, and they are required 
for normal replication. Thus, the study of the mechanisms of induction of tumors by PyV 
proteins provides insight into how a normal cell becomes a tumor cell, and these mechanisms 
may also be important in other PyV diseases and for the basic biology of the virus. 
1.1 POLYOMAVIRUSES AND DISEASE 
To date, 101 polyomaviruses (PyVs) have been found in an array of mammalian species, as well 
as birds. Most of these viruses have not been associated with disease; however, the remaining 
few PyVs can produce severe disease in the unfortunate host. Disease is commonly associated 
with suppression or underdevelopment of the immune system. In addition, with the exception of 
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one PyV (Merkel cell polyomavirus), tumors do not develop in the natural hosts under natural 
conditions. 
Polyomaviruses have been detected in many mammals; however, only six are the 
causative agents of disease. Hamster polyomavirus and murine polyomavirus (MuPyV) both 
induce tumors in younglings of the same species (Habel, 1963; Scherneck et al., 2001); though, 
this is mainly seen in the laboratory and not in wild populations (Gottlieb and Villarreal, 2001; 
Rowe, 1961). Two human PyVs, BK polyomavirus (BKV) and JC polyomavirus (JCV), replicate 
to high levels in immune-suppressed transplant patients and patients with acquired immune 
deficiency syndrome (AIDS) resulting in pathologies involving severe tissue destruction. Human 
tricodysplasia spinulosa-associated polyomavirus (TSPyV) causes spike-like growths on the skin 
of transplant patients. The recently discovered human Merkel cell PyV was found to be a 
causative agent of a rare skin cancer known as Merkel cell carcinoma. This is the first of the 
human PyVs to be validated as a cause of cancer in humans. BKV, JCV, TSPyV, and MCPyV 
are discussed further in section 1.4. 
Bird polyomaviruses are distinct from the other PyVs in their relation to disease. 
Infection with two bird PyVs has been shown to cause acute disease of young birds and is not 
associated with a compromised immune system (reviewed in Johne and Muller, 2007). 
Budgerigar fledgling disease virus is the causative agent of the disease of the same name. It is 
fatal in young Budgerigar parrots, causing hepatitis and accumulation of fluid between organs. 
Young parrots that survive have chronic disease mainly characterized by feather disorders. 
Goose hemorrhagic polyomavirus (GHPyV) can cause hemorrhagic nephritis and enteritis of 
goslings resulting in sudden death. Other bird polyomaviruses have been discovered in tissues of 
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diseased birds (Bennett and Gillett, 2014; Halami et al., 2010; Johne et al., 2006); however, 
causal links between these viruses and disease have not been tested. 
1.2 POLYOMAVIRUS LIFE CYCLE 
Initial infection by PyV is asymptomatic and produces a viremia that allows the virus to infect 
specific tissues where it becomes latent. It is not clear if this is true latency, with no replication 
and limited to no viral gene expression, or if the infection is persistent with low levels of 
replication. Reactivation of viral replication can occur with no symptoms in healthy individuals. 
PyV infections are kept in check by the immune system, as PyV-associated disease or tumors 
that develop in the natural host occur with high incidence in immunocompromised 
individuals.(Kean and Garcea, 2009) 
A productive PyV infection begins with the attachment of the virion to specific cell 
surface receptors followed by internalization through endocytosis. The virion is transported to 
the nucleus where the genome is released. The genome of PyV is a circular dsDNA of about 5 
kilo-base pairs wrapped around cellular histones to create a mini chromosome (Yaniv, 2009). A 
non-coding region physically separates and controls the expression of the early and late 
transcriptional regions (Figure 1A). The non-coding region contains promoters for transcription 
of viral genes, a bi-directional enhancer, the origin of replication, and the viral packaging signals. 
Host RNA polymerase II transcribes PyV early mRNAs. Several early transcripts can be 
produced by alternative splicing, but all PyVs have been shown to make a large T antigen (LT) 
and small T antigen (sT) (Figure 1B). PyVs infect non-dividing, differentiated cells, so the early 
LT and sT proteins bind to cellular proteins to push the cell into S phase when cellular proteins 
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for DNA replication, chromatin assembly, and nucleotide metabolism are present. LT is also 
required in all PyVs to initiate viral genome replication, to act as a helicase during replication (as 
a LT hexamer), and recruit host DNA replication proteins to the viral genome (Figure 2). 
Transition of transcription of the early region to the late region is dependent on at least two 
factors: 1) LTs ability to stimulate late region transcription (Keller and Alwine, 1984), and 2) the 
replication-dependent titration of cellular proteins that inhibit late region transcription (Liu and 
Carmichael, 1993; Wiley et al., 1993). The late region produces the viral capsid proteins 
allowing new PyV progeny virions to be assembled, which are eventually released from the cell.  
For PyVs, tumorigenesis does not benefit the virus and is the result of an infection that 
does not end in production of virus progeny. Tumorigenesis, therefore, is an accident, brought on 
by the continued expression of polyomavirus T antigen proteins that were meant to reprogram 
the cell for virus production. Accordingly, expression of the T antigen proteins independent of 
the virus also induces tumorigenesis in animal models and transformation of cells (Grossi et al., 
1982; Jat and Sharp, 1986; Saenz Robles and Pipas, 2009). 
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 Figure 1. Common features of polyomavirus genomes. 
A) PyV genomes contain a non-coding region, early transcriptional unit, and late transcriptional unit. The 
non-coding region contains bi-directional promoters for both early and late region transcription, enhancer 
elements, and the viral origin of replication. B) All polyomaviruses produce a large T antigen (LT) and 
small T antigen (sT) transcript by alternative splicing of the early region pre-mRNA. LT is created by 
removal of an intron near the 5’ end. sT reads through the 5’ splice site for the LT intron and uses an 
alternative 5’ splice site within the LT intron to remove a smaller intron. The small T stop codon is found 
before the small T intron or directly after the sT intron. Black bars represent exons, carets symbolize 
introns, and black lines signify non-translated regions of the transcript. 
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Figure 2. Functions of polyomavirus large T antigen in replication of the viral genome. 
Polyomavirus large T antigens have a conserved domain structure. The origin binding domain recognizes 
and binds to sequences within the non-coding region of PyV genomes. This facilitates formation of two 
LT hexamers on the viral DNA facing in opposing directions. The ATPase domain and zinc-binding 
domains are required to form the helicase function that allows unwinding of the viral DNA during 
replication. Each hexamer is a separate helicase. The LT protein also recruits host replication factors to 
the viral origin which form the replisome. Cellular proteins that interact directly with SV40 LT are 
shown. 
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1.3 THE CONVERGENCE OF POLYOMAVIRUS T ANTIGENS AND 
MECHANISMS OF CANCER 
A malignant tumor is a complicated thing. Many auxiliary mutations have already occurred at 
this point because several of the cellular systems that maintain the integrity of the genome have 
been compromised. Therefore, although there is much to be learned from large scale tumor 
sequencing projects like The Cancer Genome Atlas, this data is generally not useful to 
understand the essential mutations at the initial stages of development since samples are 
generally taken from late stage tumors. In addition, the critical altered pathways within the cell 
that are required to maintain the cancerous state cannot be readily deduced from the complicated 
picture of a fully developed tumor. Introducing individual mutations found in cells from these 
tumors into a cell culture system to understand the effects of each is tedious. PyV T antigen 
induced transformation and tumorigenesis offers a controlled way of taking a normal cell and 
making it cancerous.  
PyV T antigens reprogram cells by binding to proteins that are key regulators of cellular 
signaling networks. Many of these signaling networks are also perturbed in cancer cells. In fact, 
several of the outcomes of reprogramming of cells in cancer and by PyV T antigens overlap 
(Figure 3), and many cellular proteins directly affected by PyV T antigens are found to be 
mutated or otherwise altered in cancers. For example, many PyV LT proteins inhibit the 
functions of the tumor suppressors pRB and p53, which are also frequently mutated in cancers 
(reviewed in Di Fiore et al., 2013; Olivier et al., 2004). The result of inhibition of these proteins 
leads to proliferative signaling and evasion of cell death in T antigen expressing cells and cancer 
cells. 
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The PyV T antigens reveal different combinations of pathways that, when disturbed, lead 
to transformation. As discussed in more detail in sections 1.5 and 1.6, the T antigens of the two 
most well studied polyomaviruses, SV40 and Murine PyV, interact with different sets of cellular 
pathways to illicit transformation and tumorigenesis. And, it is possible the T antigens of newly 
discovered polyomaviruses will promote transformation in ways that have not been seen 
previously. Discovering the mechanisms of these polyomavirus T antigens will give us a better 
understanding of the many ways a single cell can transform to a cancerous state.      
1.3.1 How does transformation relate to tumorigenesis? 
Transformation, in this dissertation, refers to the ability of a cell in culture to grow and 
proliferate in conditions where it otherwise would not. Several in vitro assays have been used to 
determine transformation of cultured cells by PyV T antigens. Each is affiliated with a distinct 
characteristic of growth that is not found in “normal” cells, but can be seen in cells isolated from 
tumors or expressing different oncogenes. While some of these assays create conditions that may 
be similar to some tumors, it is not always clear how these in vitro situations directly relate to the 
in vivo environment. Yet, transformation assays may be used as predictors of tumorigenic 
capability as discussed at the end of this section. Furthermore, it appears that these assays are 
distinct in that the ability to transform in one assay does not necessarily mean that transformation 
will occur by another assay. 
Cells taken directly from the tissue of an organism generally have a limited lifespan in 
culture. After a given number of population doublings these “primary” cells will go into a crisis 
where they cease proliferation and begin to die. After expression of a mutated cellular protein or 
viral transforming protein, the lifespan of the cells can be tested by serial passaging in culture. 
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Cells that can be continually passaged without ever reaching crisis are termed immortal. 
Sometimes the cells are greatly delayed in the time to crisis and the mutation or viral protein 
expressed is said to have conferred an extension of life to the cells. Due to the length of time 
required to perform the transformation assays described below, immortalization or extension of 
life is a common prerequisite.   
Dense focus formation assays look for transformation in the form of cells that continue 
to grow even after a monolayer of cells has formed on a tissue culture plate, resulting in dense 
clusters of cells, or foci. This transformation phenotype is termed loss of contact inhibited 
growth. Tumor cells can also acquire the ability to ignore normal inhibitory growth signals, 
allowing them to grow to high numbers. 
Another form of transformation involves testing the ability of cells to grow in a nutrient-
limited environment. This is most often achieved by limiting the amount of serum in culturing 
medium; therefore the assay is generally referred to as growth in low serum. Nutrient 
deprivation is also seen in stages of some tumors before angiogenesis creates new blood vessels 
(bringing fresh supplies of nutrients). Therefore cells of early stage tumors must evolve to grow 
in the nutrient limited environment.   
Most cells in culture require attachment to a solid surface (i.e. a plastic tissue culture 
dish) to proliferate. When these cells are suspended they will not proliferate, but can still survive; 
transformed cells, on the other hand, will continue to proliferate in suspension to form colonies. 
Suspension is commonly achieved by mixing normal growth medium with a low percentage of 
agar. This transformation assay is termed the soft agar or anchorage independence assay. 
Finally, cells that achieve transformation by one of the assays previously described are 
tested for the ability to form tumors in nude mice. Transformed or non-transformed cells are 
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injected into immunocompromised mice and tumor development is monitored over several 
weeks or months; fully transformed cells will form tumors within a few weeks, while non-
transformed or partially transformed cells will not form tumors. 
Although these assays attempt to simulate “body-like” conditions, the growth and 
manipulation of cells in a petri dish fundamentally alters the properties of that cell. Therefore, it 
cannot be said with complete certainty that transformation resulting from manipulation of a cell 
in culture is directly related to what happens to form a tumor cell. For a further discussion of the 
“cellular uncertainty principle” see (Ahuja et al., 2005). Nevertheless, transformation of cells in 
culture has been shown to be a good predictor of tumorigenic capability. Two observations 
support this statement. First, cells that were transformed in vitro also formed tumors in multiple 
publications that tested cells expressing T antigen for transformation with either the dense focus 
or soft agar assays and formation of tumors in nude mice (Hahn et al., 2002; Nguyen et al., 2014; 
Schuurman et al., 1992; Soejima et al., 2003; Yeh et al., 2004). Second, cell culture 
transformation has been used for decades to determine the carcinogenic nature of chemical 
compounds with a good rate of success (Combes et al., 1999; Creton et al., 2012). Thus, in vitro 
transformation remains an useful way to study the molecular disturbances that create a cancer 
cell. 
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Figure 3. Cancer and PyV T antigen expression reprogram cells resulting in similar outcomes. 
Decades of study of cancer and tumorigenesis revealed several defining features that are accumulated in 
cells of tumors (blue arrows). T antigens of polyomaviruses reprogram cells to proliferate and avoid death 
signals during infection and transformation similar to cancer cells (purple arrows). T antigen transformed 
cells in culture and from tumors also display genome instability and deregulation of cellular energetics 
(black dashed arrows). T antigen induced tumors also require angiogenesis and can metastasize in some 
models (brown dashed-arrows). 
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1.4 HUMAN POLYOMAVIRUSES 
Thirteen polyomaviruses have been identified in humans, eleven of which have been discovered 
in the past seven years. Studies indicate that initial infection with PyVs occurs early in life, and 
that seroprevalence of human PyVs in the adult population can be from 35% to 92% (reviewed in 
DeCaprio and Garcea, 2013). Overall, the genomes of human PyVs are similar to the canonical 
primate SV40 polyomavirus in that they all appear to code for at least the large and small T 
antigen proteins in the early region and three capsid proteins in the late region. Several of the 
human PyVs however, are dissimilar in sequence and protein expression compared to both SV40 
and other human PyVs. In particular, the LT proteins of the 13 human PyVs differ enough from 
each other (Figure 4) to suggest that their ability or mechanisms to induce tumors may also vary. 
Investigation of each human PyV’s transformation potential in cell culture could lead to new 
insights into pathways that are involved in transformation of the normal cell to a cancerous cell.   
BKV and JCV were the first human PyVs identified both in the early 1970s. For 
complete reviews of BKV and JCV disease and epidemiology see (Hirsch et al., 2013; Rinaldo et 
al., 2013). BKV was isolated from the urine of a patient who had undergone transplantation 
surgery several months prior (Gardner et al., 1971). BKV causes disease in 1-15% of transplant 
patients mainly stemming from viral replication in the kidneys or bladder. The two most 
common diseases are polyomavirus-associated nephropathy (PVAN) in kidney transplant 
patients and polyomavirus-associated hemorrhagic cystitis in stem cell transplant patients. The 
recommended treatment is to simply stop immunosuppressive drugs to allow the immune system 
to combat the virus; however, this could also lead to rejection of the transplant. JCV, on the other 
hand, was first found in the brain of a patient with Hodgkin’s disease and progressive multifocal 
leukoencephalopathy (PML) (Padgett et al., 1971). Since then, it has been shown that JCV 
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reactivation is generally found in central nervous system tissues and the kidney. JCV has been 
linked to PML in patients with various immune system dysfunctions (e.g. AIDS, immune 
suppressive drugs due to transplant or rheumatoid arthritis). JCV can also be a causative agent of 
PVAN, but it is less common than BKV associated PVAN. Safe and effective antiviral therapies 
for illness caused by both viruses are lacking. 
BKV and JCV viral DNA and, in some cases, LT protein have been detected in many 
human tumors, leading to the question of whether these viruses are involved in human cancer 
(Coelho et al., 2010; Hachana et al., 2012; Moens et al., 2014). The answer is not clear cut since 
BKV and JCV DNAs can be detected in both tumor and non-tumor samples in some studies, and 
because of the high seroprevalence and detection of these two viruses in healthy people 
(reviewed in Dalianis and Hirsch, 2013). One emerging hypothesis is that human PyVs can act as 
co-factors in human tumor progression as compared to a direct cause and effect role seen with 
JCV and PML. Moens et al. have proposed that human PyVs may act as co-factors to an 
additional viral infection in the same cell/tissue, for example Epstein-Barr herpesvirus or human 
papillomavirus infections, and they speculate that the products of the two viruses could work 
together to promote oncogenic transformation. Alternatively, Coelho et al. argue that JCV viral 
proteins act as cofactors for colorectal cancer by facilitating and/or enhancing key mutations of 
cellular proteins to promote tumorigenesis at different stages of tumor progression. 
The human Merkel cell polyomavirus (MCPyV) was first identified in silico in 2008 
using the digital transcriptome subtraction technique from a database of normal and cancerous 
tissues (Feng et al., 2008). MCPyV DNA has since been found in 80-97% of all Merkel cell 
carcinomas, and several lines of evidence now indicate that MCPyV is the first human oncogenic 
polyomavirus (reviewed in Spurgeon and Lambert, 2013). Merkel cell carcinoma (MCC) is a 
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rare skin disease and old age and immune system compromise are both risk factors, suggesting 
that immune surveillance is important in keeping MCPyV in check. The MCPyV early region 
produces at least four T antigens, and it is quite divergent from SV40, BKV, or JCV. 
Furthermore, the early regions of MCPyV found in MCC are mutated in a way that prevents 
expression of the full length LT and other T antigen proteins (Cheng et al., 2013; Shuda et al., 
2008). This immediately suggests a difference in transformation strategy compared to other well 
characterized PyVs. Indeed, several reports on the transforming abilities of the four T antigens 
make it quite clear that this virus is unique (reviewed in Spurgeon and Lambert, 2013; Stakaitytė 
et al., 2014).  
Tricodysplasia spinulosa-associated polyomavirus (TSPyV) causes a skin disease of the 
same name in severely immunocompromised hosts (van der Meijden et al., 2010). TSPyV is 
rarely detected in the skin of healthy people but seroprevalence is high suggesting that the skin 
may not be the main reservoir for the virus. Viral load is high in diseased tissue, and instead of 
tissue destruction like with BKV and JCV disease, TSPyV replication produces hyper 
proliferation of specific hair follicle cells which culminate in spiny follicular papules on the face, 
neck, and trunk of the body. Currently, no studies have looked at expression of the TSPyV early 
region or individual T antigen proteins in cell culture to ascertain the transforming potentials. 
(Kazem et al., 2013) 
The first new human polyomaviruses to be discovered in over 30 years since the isolation 
of BKV and JCV were the Karolinska Institute polyomavirus (KIPyV) and Washington 
University polyomavirus (WUPyV) (Allander et al., 2007; Gaynor et al., 2007). Both viruses 
were identified using high-throughput sequencing methods on DNA from respiratory samples, 
and have since been detected in respiratory tract, stool, and blood samples from every continent 
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(Babakir-Mina et al., 2013). There has been no clear evidence yet to associate WU and KI PyV 
infection with disease in healthy or immune-compromised people. By sequence, WU and KI 
PyVs are more closely related to each other than BKV, JCV, or SV40 (Figure 4 and (Gaynor et 
al., 2007)). The transforming properties of the T antigens from WU and KI have not been 
investigated; although, one study showed association of tagged WUPyV T antigen proteins with 
cellular pRb and p53 by tandem affinity purification coupled with mass spectrometry (TAP-MS) 
(Rozenblatt-Rosen et al., 2012). 
  Human polyomaviruses 6 and 7 (HuPyV6, HuPyV7) were isolated from skin swabs of 
healthy patients (Schowalter et al., 2010), and appear to create a new phylogenetic branch of the 
polyomavirus tree as do WU and KI PyVs (Figure 4 and (Schowalter et al., 2010)). They have 
not been associated with any disease to date, but appear to have a high seroprevalence. The T 
antigens of these viruses have not been investigated for their transforming capabilities, but one 
study found that HuPyV6 T antigens associate with p53 and pRb by TAP-MS, while HuPyV7 
only showed an association with pRb (Rozenblatt-Rosen et al., 2012). 
Several other polyomaviruses have been found in various human samples, none of which 
have yet been shown to directly cause a human pathology. The New Jersey polyomavirus 
(NJPyV) complete genome was uncovered by high-throughput sequencing from a skin lesion of 
a transplant patient, and it is the latest polyomavirus discovery (Mishra et al., 2014). Human 
polyomavirus 12 (HuPyV12) was isolated from resected liver tissue and subsequently detected in 
intestinal tissue samples as well as one stool sample (Korup et al., 2013). Preliminary 
seroprevalence studies showed 15-33% of adults tested were positive for HuPyV12 antibodies 
(Korup et al., 2013). Human polyomavirus 9 (HuPyV9) was discovered by high throughput 
sequencing and pieced together by nested PCR of multiple blood and urine samples (Scuda et al., 
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2011). This virus is most closely related to a primate polyomavirus, lymphotropic papovavirus 
(LPV), which is known to have a tropism for B lymphocytes and is a potent transformer in 
animal models and cells culture. HuPyV9 T antigens have yet to be assessed for transformation 
potential. Malawi polyomavirus (MWPyV, other isolates are known as Mexico polyomavirus 
(MXPyV) and human polyomavirus 10 (HuPyV10)) and Saint Louis polyomavirus (STLPyV) 
were isolated from human stool samples (Buck et al., 2012; Lim et al., 2013; Siebrasse et al., 
2012; Yu et al., 2012). A small study showed that 23-75% of people tested positive for reaction 
to MWPyV depending on age (Berrios et al., 2014). The same study also performed preliminary 
experiments that suggest association of MWPyV T antigens with cellular proteins similar to 
SV40 T antigens, but unlike SV40 T antigens, those of MWPyV did not transform human cells 
in culture.  
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Figure 4. Evolutionary tree of human polyomavirus large T 
antigens. 
Human PyVs LT sequences are diverse, which may suggest unique 
ways of inducing transformation. An alignment of all 13 human PyV 
large T antigens was performed using Muscle. The alignment was used 
to build a maximum likelihood phylogenetic tree with default 
parameters in the MEGA 6 software package.  
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1.5 THE SV40 LARGE T ANTIGEN MODEL OF TRANSFORMATION 
The SV40 polyomavirus, which naturally infects species of Asian macaques, was discovered as a 
contaminant of primate cell lines used to create the polio vaccine (Sweet and Hilleman, 1960). 
This virus produces three T antigen species: LT, sT, and 17kT (Figure 5). The LT of SV40 is 
sufficient to induce full transformation in most established cells and tumors in transgenic models, 
while some systems require both the LT and sT (e.g. normal human cells). In general, two human 
PyVs, BKV and JCV, follow suit with both the structure and mechanisms of transformation seen 
with SV40.  
The SV40 LT is a 708 amino acid phosphoprotein with distinct structural domains 
(Figure 6). The J domain is a conserved DNAJ co-chaperone, containing the required HPD motif 
for binding cellular chaperone Hsc70 (Srinivasan et al., 1997). The J domain is connected to the 
origin binding domain (OBD) by a flexible string of amino acids, called the N-terminal linker 
region. The N-terminal linker serves as a hub for binding of several cellular proteins to LT. The 
origin binding domain is followed by the zinc and AAA+ ATPase domains. These two domains 
are required for the helicase function of all LT proteins. In addition, LT binds to p53 at the 
surface of the ATPase domain (Lilyestrom et al., 2006). Following the ATPase domain is an 
unstructured stretch of amino acids known as the variable region and host range region (VHR). 
In SV40, this region has mainly been associated with replication. Only three regions of SV40 LT 
have been identified by genetic studies as essential for transformation: the J domain, the N-
terminal linker region, and the p53-binding region on the ATPase domain. 
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Figure 5. Genome organization and transcript map of large T antigen transforming viruses. 
SV40, BKV, and JCV express similar large T antigen, small T antigen, and late region proteins (VP1, 
VP2, VP3, agno). Alternative splicing patterns of the early region T antigens are shown. Thick patterned 
arrows represent exons, while thin black lines represent introns. 
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1.5.1 Interaction with pRB family proteins 
Together the LT J domain and LxCxE motif within the N-terminal linker region induce cell 
proliferation by inactivating inhibitory pRB-E2F complexes (Figure 6). The pRB family of 
proteins includes pRB, p107, and p130. These three proteins coordinate to regulate the transition 
from the G1 to S phase of the cell cycle by directly binding and inhibiting the E2F transcription 
factor proteins. pRB specifically binds to activator E2Fs 1, 2, and 3, while p107 and p130 bind to 
repressor E2Fs 4 and 5. Release of the E2Fs occurs when pRB proteins are phosphorylated by 
cyclin dependent kinases and results in transcription of S-phase genes and, ultimately, DNA 
synthesis. 
SV40, JCV, and BKV LTs bind to all three pRB proteins through an LxCxE motif 
located in the N-terminal linker region (Chellappan et al., 1992; Dyson et al., 1990; Harris et al., 
1996; Tavis et al., 1994; Zalvide and DeCaprio, 1995). The requirement for the LxCxE motif in 
transformation by SV40 LT is well-documented by mutagenesis studies (Chen and Paucha, 
1990; Srinivasan et al., 1997; Zalvide and DeCaprio, 1995). The importance of this motif is also 
shown by the fact that the same motif is required for other viral and cellular proteins to bind to 
pRB proteins (Chellappan et al., 1992; Singh et al., 2005).  
SV40 LT specifically binds pRB in the under-phosphorylated forms thereby preventing 
its action during the G0/G1 phase of the cell cycle and allowing G1 to S transition (Ludlow et al., 
1989; Ludlow et al., 1990). Interaction with LT causes dephosphorylation of p130 and p107 (Lin 
and DeCaprio, 2003; Stubdal et al., 1996) and potentially p130 degradation (Stubdal et al., 
1997). The binding of pRB proteins to the LT LxCxE is not sufficient to activate E2F-mediated 
transcription; this function also requires the J domain of LT (Pipas et al., 1983; Srinivasan et al., 
1997; Zalvide et al., 1998). Hsc70 binding at the J domain and subsequent chaperone activity has 
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been shown to specifically dissociate p107/E2F4 and p130/E2F4, but not pRB/E2F complexes 
(Sullivan et al., 2004). In line with this finding, double knockout p107 -/- ; p130 -/- MEFS that 
expressed SV40 LT with an LxCxE mutation were unable to grow in low serum and did not 
confer a growth advantage in normal serum, suggesting that pRB binding is required for these 
transformation phenotypes. But, when a J domain mutant of LT was expressed, both low and 
normal serum growth was restored (Stubdal et al., 1997). This suggests that either the J domain 
does not participate in dissociation of the pRB-E2F complex, or that dissociation of pRB/E2F is 
not required for transformation. 
A chaperone model of the J domain-dependent dissociation of p130/E2F and p107/E2F 
complexes has been proposed (reviewed in Sullivan and Pipas, 2002). It begins with LT binding 
to p130/p107 through the LxCxE motif and Hsc70 through the HPD motif within the J domain. 
Hsc70 uses the energy gained from hydrolyzing ATP to dissociate E2F from p130/p107. This 
frees the E2F from the complex. The dissociation removes repressive complexes from E2F 
regulated cell cycle genes, which allows the activator E2Fs to bind and stimulate transcription 
(Figure 6). In accordance, cells that express SV40 LT show activation of a host of E2F regulated 
genes involved in cell cycling, DNA replication, and chromatin modification (Cantalupo et al., 
2009). 
1.5.2 Inhibition of p53 
p53 is arguably the most well-studied tumor suppressor protein. It is a transcription factor that 
senses several kinds of cell abnormalities. In response, p53 activates genes like p21 that mediate 
growth arrest to allow the cell time to repair, or, when circumstances are dire, it activates cell 
death mechanisms through transcription of several well-known apoptosis associated genes, 
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including Bax, Noxa, and Puma (Brady et al., 2011). SV40 large T antigen activates p53 through 
at least two mechanisms. First, dysregulation of the pRB family activates p53 most likely by an 
E2F-dependent mechanism (Polager and Ginsberg, 2009). Second, SV40 LT expression results 
in activation of DNA damaging sensors that, in turn, activate p53. This mechanism can occur 
though both Bub1-dependent and -independent mechanisms (Boichuk et al., 2010; Hein et al., 
2009).  
Although p53 is activated in LT cells, as evidenced by multiple post-translational 
modifications (Borger and DeCaprio, 2006), it is prevented from transactivating p53-secific 
promoters (Jiang et al., 1993; Segawa et al., 1993) because LT binds to the DNA binding domain 
of p53 (Lilyestrom et al., 2006). Thus, p53 cannot induce genes that would lead to apoptosis, 
senescence, or growth arrest in cells with LT. In contrast to other DNA tumor viruses, which 
remove p53 from the cell by inducing its degradation, SV40 LT stabilizes p53, and therefore p53 
is readily detected by Western blot. Both BKV and JCV LT bind and inhibit p53 transactivation 
in a similar way (Bollag et al., 1989; Krynska et al., 1997; Nakshatri et al., 1988)  
Two patches of residues on the surface of the ATPase domain of SV40 LT mediate 
binding to p53 – these are within a.a. 351-450 and 533-626. Mutation of these residues prohibits 
growth to high density in normal and low serum conditions, dense focus formation, and 
anchorage independence (Ahuja et al., 2009; Peden et al., 1989). However, extension of life and 
rescue of proliferation of serum-deprived primary cells occurs in the absence of p53 binding 
(Tevethia et al., 1998; Tevethia et al., 1988; Thompson et al., 1990), showing that p53 inhibition 
is not required for some aspects of cellular transformation. 
LT has also been shown to be associated to CBP/p300 transcriptional co-activators 
through its binding to p53. This association results in acetylation of lysine 697 within the host 
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range region of SV40 LT (Poulin et al., 2004) and increased acetylation at specific residues on 
cellular histones (Saenz Robles et al., 2013). It is not clear if CBP and p300 are required to 
complex with SV40 LT and p53 to transform cells.  
Although LT binding to p53 is undoubtedly important for transformation of cells, this 
may not be the whole story. Expression of a fragment of SV40 LT containing only the J domain 
and N-terminal linker was able to prevent p53 transactivation of a CAT reporter after UV 
stimulation, suggesting this fragment is capable of regulating p53-mediated transcription 
independently (Rushton et al., 1997). Also, inhibition of p53 through expression of dominant-
negative p53 was unable to transform cells in the presence of a similar N-terminal fragment 
(Sachsenmeier and Pipas, 2001), which points to additional roles of functional p53 in 
transformation by SV40 LT. 
1.5.3 Other proteins that affect transformation by SV40 LT: Cul7 and Bub1 
Cul7 is a scaffold protein associated with the Cullin-RING E3 ubiquitin ligase complex. Genetic 
studies in mice have shown that loss of Cul7 results in severe pre- and post-natal retardation 
(Cheng et al., 2009). SV40 LT was shown to bind to Cul7 by immunoprecipitation from cellular 
lysates (Ali et al., 2004; Kohrman and Imperiale, 1992). Mutations within SV40 LT revealed a 
loosely defined set of amino acids that span the J domain and N-terminal linker region that 
contribute to Cul7 binding (aa. 69-83, 98, and 101; (Ali et al., 2004; Kasper et al., 2005)). The 
F98A mutant of SV40 LT that does not immunoprecipitate with Cul7 is impaired in inducing 
anchorage independent and low serum growth in primary murine embryo fibroblasts (Ali et al., 
2004). A full understanding how this interaction affects transformation is lacking; however, a 
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recent publication suggests IRS1, a component of the insulin growth factor receptor pathway, as 
a target of Cul7 inhibition by SV40 LT (Hartmann et al., 2014). 
Bub1 interaction with SV40 LT was discovered through a yeast-two-hybrid screen, and 
subsequently verified by co-immunoprecipitation from cell lysates. Deletion of amino acids 89-
97 or mutation of individual tryptophans within this region (which are conserved in several other 
PyV LTs (Figure 10)) prevent association of Bub1 and LT. Immortalization of rat embryo 
fibroblasts by SV40 LT is not affected when Bub1 binding is prevented; however, dense focus 
formation of an established rat cell line may be inhibited (Cotsiki et al., 2004). 
Bub1 is a kinase that participates in the spindle assembly checkpoint of mitosis (Williams 
et al., 2007). This checkpoint is activated during anaphase if kinetochores are not properly 
attaching chromosomes to spindle microtubules. In addition, Bub1 may have other roles in DNA 
repair and replication (Hu et al., 2013). Therefore, it is not surprising that Bub1 binding to SV40 
LT significantly increases the incidence of tetraploidy in cultured cells (Hein et al., 2009), as 
well as several other hallmarks of chromosomal instability (Hu et al., 2013). Of note, Hanahan 
and Weinberg discuss genome instability as an enabling characteristic of cancer, allowing 
genetic mutations to accumulate more readily (Hanahan and Weinberg, 2011). Although it is not 
clear how Bub1 interaction with SV40 LT contributes to the immediate transformation of cells in 
vitro, it can easily be envisioned that the chromosomal instability resulting from this interaction 
plays a part in LT-induced tumorigenesis. 
1.5.4 SV40 small T antigen contributes to cellular transformation 
SV40 sT is identical to LT for the first 82 amino acids, which comprise the J domain. The J 
domain is functional, as it can stimulate the ATPase activity of Hsc70 in vitro (Srinivasan et al., 
 25 
1997); however, SV40 sT does not contain an LxCxE motif and cannot bind to pRB proteins. 
The remaining amino acids are unique to small T. This unique region contains two cysteine 
clusters (CxCxxC) that confer stability to the small T proteins through binding of two zinc ions, 
and it binds to the cellular protein phosphatase 2A complex (PP2A) through Cys-97, Pro-101, 
Cys-103, and residues 110-119 (Das and Imperiale, 2009). BKV and JCV sT proteins also bind 
to PP2A, but they also have LxCxE motifs in the unique region of small T that can bind to pRB 
proteins (Bollag et al., 2010); however the contribution to transformation of pRB binding by JCV 
or BKV sT is not known.  
SV40 sT is capable of cooperating with LT to transform cells. It can enhance 
transformation when levels of LT are too low to fully transform cells (Bikel et al., 1987). In 
addition, normal human cells are fully transformed only when both LT and sT are combined with 
activated Ras and hTERT (Hahn et al., 2002). The binding to PP2A is arguably the most 
important role of sT in transformation, since mutations that prevent PP2A binding abolish its 
ability to complement LT (Hahn et al., 2002). 
PP2A is comprised of 3 subunits: A, B, and C. In mammals there are 2 isoforms each of 
the core components of the complex, regulatory A and catalytic C subunits (Aα, Aβ, Cα, Cβ). 
The B subunits are much more numerous and confer substrate specificity, subcellular 
localization, and regulation to the phosphatase. Specific combinations of the PP2A complex 
function in normal cells to regulate many pathways, including apoptosis and cell survival, cell 
cycle regulation, cell adhesion, the DNA damage response, and embryonic development 
(reviewed in Seshacharyulu et al., 2013). 
SV40 sT specifically binds to complexes containing Aα subunits (Andrabi et al., 2011). 
Binding to the A subunit either displaces or prevents the B subunits from binding. This results in 
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inhibition of the phosphatase activity and, thus, dysregulation of many growth factor signaling 
pathways. A few downstream proteins that are activated as a result of PP2A inhibition by sT 
have been shown to play a role in transformation. In one system using normal human cells, the 
stabilization of c-myc induced by SV40 sT was required for anchorage independent 
transformation and tumor formation in immunocompromised mice (Yeh et al., 2004). In mouse 
cells and human fibroblasts, SV40 sT specifically activates AKT in a PP2A and PI3K dependent 
manner leading to transformation (Rodriguez-Viciana et al., 2006; Zhao et al., 2003).  
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Figure 6. Cellular proteins that contribute to transformation by large T antigen and small T antigen 
of SV40.  
The three transforming regions of SV40 LT are the J domain, the N-terminal linker region, and the 
ATPase domain. These regions bind the cellular proteins shown resulting in activation of cell 
proliferation and prevention of cell death mechanisms as described in the text. The SV40 small T antigen 
C terminus is required for PP2A binding. Binding to PP2A is necessary for sT to complement LT in 
transformation. As a result of PP2A binding to sT, the transcription factor c-myc is stabilized and AKT is 
activated. Dashed arrows indicated downstream effects, while solid arrows represent direct binding. 
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1.6 THE MURINE PYV MIDDLE T ANTIGEN MODEL OF TRANSFORMATION 
The early region of MuPyV produces four T antigen species: LT, sT, middle T (mT), and tiny T 
(Figure 7). While LT and sT contribute to transformation, it is mT that is required for full 
transformation in culture and tumor formation. Hamster PyV is the only other PyV to produce 
and transform cells through the action of mT (Bastien and Feunteun, 1988; Goutebroze and 
Feunteun, 1992). 
Middle T antigen is a membrane-associated phosphoprotein that interacts with several 
cellular proteins involved in critical signaling pathways to induce transformation. In cell culture, 
mT can transform established rodent cell lines on its own but primary cells require small T or 
large T to complement mT (Marti and Ballmer-Hofer, 1999; Rassoulzadegan et al., 1982; 
Treisman et al., 1981). Membrane association is critical for mT as deletion of the C-terminal 
hydrophobic region completely abolishes transforming activity (Novak and Griffin, 1981). 
Phosphorylation of specific tyrosine residues is also critical for middle T to bind to certain 
cellular partners, and mutations of these residues often alter transformation and tumorigenesis 
(reviewed in Fluck and Schaffhausen, 2009). A few of the cellular partners have been shown to 
be required for transformation by mT (summarized in Figure 8). While some of the interactions 
discussed below are needed universally for transformation by mT, others are only important in 
certain cell types or for tumor formation in animal models. 
MuPyV mT exerts its transforming power by interaction with PP2A and phosphotyrosine 
kinases. Binding of proteins to middle T occurs in a sequential fashion where PP2A must bind 
first followed by a Src tyrosine kinase. c-Src phosphorylates mT at specific residues, which then 
become sites for binding to other cellular proteins. Mutations that prevent PP2A, c-Src binding, 
c-Src phosphorylation activity abolish transformation by mT (Carmichael et al., 1984; Guy et al., 
 29 
1994; Pallas et al., 1990; Walter et al., 1990). Phosphorylation at tyrosine 250 allows mT to bind 
to the ShcA family of proteins and leads to activation of MAPK pathway, although which 
downstream targets contribute to transformation is unknown (Dilworth et al., 1994; Ichaso and 
Dilworth, 2001). Overall, the signaling through Shc proteins activates cell proliferation. 
Phosphorylation at tyrosine 315 mediates interaction with the p85 subunit of 
phosphatidylinositol 3-phosphate kinase (PI3K). Middle T that cannot bind PI3K is severely 
defective in transformation (Markland and Smith, 1987). PI3K is activated and produces the 
PIP3 as a result of association with mT. The PIP3 molecule targets several serine/threonine 
kinases leading to activation of Rac GTPase and AKT, which are expected to activate many 
downstream targets (reviewed in Fluck and Schaffhausen, 2009). Phosphorylation of tyrosine 
322 allows mT interaction with phospholipase Cγ1 (PLCγ1), and mutation of this residue had an 
effect on growth in low serum of established cells (Su et al., 1995). PLCγ1 enzymatic activity is 
stimulated in response to mT binding, but the mechanism of transformation by this pathway is 
unknown (Su et al., 1995). 
In comparison to SV40, roles of MuPyV LT and sT are very different. The contribution 
of each T antigen to transformation is summarized in Figure 8. MuPyV LT protein binds and 
disrupts pRB-E2F complexes (Sheng et al., 1997); however, this mechanism is only required for 
transformation in primary cells. This is in stark contrast to mutants of the LxCxE motif in SV40 
LT which abolish interaction with pRB proteins and full transformation. Also, SV40 LT’s direct 
inhibition of p53 is necessary for several transformation phenotypes, but none of the MuPyV T 
antigens directly inhibit p53. Even though it does not bind to p53, MuPyV LT alone can 
immortalize cells (Jat and Sharp, 1986; Rassoulzadegan et al., 1983). MuPyV sT complements 
mT by preventing inhibition of ARF-mediated activation of p53, which is induced by mT 
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expression in rat cells. The inhibition of the ARF pathway was dependent on sT binding to PP2A 
(Moule et al., 2004).  
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Figure 7. Genome organization and transcript map of  middle  T antigen transforming viruses. 
Murine polyomavirus and hamster polyomavirus are the only two PyVs that have produce a middle T 
antigen protein. Both also produce a large and small T antigen, as well as capsid proteins VP1, VP2, and 
VP3. MuPyV also produces Tiny T. Alternative splicing patterns of the early region T antigens are 
shown. Thick patterned arrows represent exons, while thin black lines represent introns. 
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Figure 8. Murine PyV T antigens interfere with several cellular proteins to induce transformation. 
Middle T antigen is required for transformation, while sT and LT play supporting roles. Each viral protein 
binds to one or more cellular proteins that results in modulation of signaling pathways as described in the 
text. mT is found associated to membranes mainly in the cytoplasm. Binding of PP2A is followed by 
association with c-src. The phosphotyrosine activity of s-src phosphorylates mT at specific Y residues. 
Phosphotyrosines on mT provide binding sites for mitogen-activated signal transduction proteins to bind. 
These proteins become activated; ultimately inducing cell proliferation and survival. Some mT binding 
proteins have been shown to have an effect on transformation, but the mechanism of action is unknown 
(?). sT complements mT transformation by inhibiting p53 activation normally mediated by ARF in mT 
expressing cells. LT can immortalize cells without mT or sT present. The only defined activity of MuPyV 
LT is the inactivation of pRB-E2F complexes by the Hsc70-J domain dependent mechanism described for 
SV40 LT. Dashed arrows indicated downstream effects. 
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1.7 BREAKING AWAY FROM THE MODEL 
The study of transformation by other polyomaviruses has begun to uncover new models and 
discrepancies with existing models of transformation put forth by SV40 and MuPyV. One 
example is the Merkel cell PyV sT. In SV40 and MuPyV, sT does not fully transform cells 
independent of other T antigens. MCPyV sT, on the other hand, is fully capable of transforming 
rodent cells in culture to dense focus formation and anchorage independence. Furthermore, 
transformation by sT was independent of PP2A or Hsc70 binding (Shuda et al., 2011). Several 
lines of evidence indicate that MCPyV is the first human oncogenic polyomavirus (reviewed in 
Spurgeon and Lambert, 2013); therefore, understanding the unique mechanisms of 
transformation by these T antigens will give insight directly into a human cancer. 
A standing observation that has yet to be fully explained is that of the reduced 
transformation ability of BKV and JCV T antigens when compared to SV40. The LTs of BKV 
and JCV are about 70% identical in amino acid sequence to SV40 LT, and they contain the same 
domain structure and important motifs (Pipas, 1992). They both bind pRBs and release E2Fs, 
and bind and inhibit p53 (Bollag et al., 1989; Harris et al., 1996; Harris et al., 1998; Tavis et al., 
1994). The Frisque group and others have performed many comparisons of JCV, SV40, and 
hybrid SV40-JCV LTs in transformation assays that have highlighted this enigma. These studies 
showed that any time regions of the SV40 LT were swapped for JCV LT there was a reduction in 
transformation, and that JCV LT may form less stable complexes with p53 (Bollag et al., 1989; 
Haggerty et al., 1989; Sullivan et al., 2000; Tavis et al., 1994; Trowbridge and Frisque, 1993). 
Fewer comparisons of BKV and SV40 have been performed, but they all show less robust 
transformation (Bollag et al., 1989; Harris et al., 1996; Hayashi et al., 2001). It is possible that 
BKV and JCV LT do not bind as well to pRB or p53 proteins; however, the experiments required 
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to prove this have not been performed. Some of these reports cite a lower protein expression for 
either JCV or BKV LT as the reason for the inability to transform as well as SV40, however 
there has been no mechanism uncovered to explain why these LT protein levels would be lower 
or how less LT would cause the transformation differences. 
A final issue that has yet to be resolved is how the LPV T antigens transform cells. 
Infection with LPV was shown to transform hamster embryo cells to growth in low serum, and to 
some extent, anchorage independence (Takemoto and Kanda, 1984). In addition transgenic mice 
expressing the LPV early region developed choroid plexus tumors and lymphomas, similar to 
SV40 (Chen et al., 1989). The overall genomic structure resembles that of SV40; however, the 
LPV LT protein shares little sequence identity with SV40 or MuPyV proteins (Figure 9). 
Unfortunately, the roles of the individual LPV T antigens in complex formation have not been 
investigated, and the few studies of the early region in transformation give mixed results about 
the LT’s ability to bind p53 (Kang and Folk, 1992; Symonds et al., 1991). Interest in LPV has 
reemerged since a new human PyV, HuPyV9, with similarity to LPV was recently discovered 
(Scuda et al., 2011). Further investigation of LPV may give insight into the transforming 
potential and mechanisms by HuPyV9. 
This thesis aims to unravel some the mysteries of BKV, JCV, and LPV transformation. 
Specifically the goal is to understand if domains of the LTs of these viruses affect transformation 
in the same way as SV40. First, the J domain and N-terminal linker regions of each virus are 
investigated for their ability to transform independent of the rest of the LT protein to determine if 
conservation of sequence relates to conservation of transformation function. Second, I take a 
closer look at the most divergent region of SV40 and JCV LT proteins, the variable linker and 
host range region, to see if it plays a role in the recorded discrepancy in transformation potency. 
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Investigations of the T antigens of these viruses may give insight into new mechanisms of 
transformation in virus and non-virus associated cancers.    
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2.0  MATERIALS AND METHODS 
2.1 CLONING OF T ANTIGENS INTO EXPRESSION PLASMIDS 
The early regions (ER) from SV40, JCV, BKV, and LPV viral genomes (accession numbers 
listed in Table 1) were PCR amplified using specific primers (Table 2) and cloned into the 
pLenti6.3-TOPO vector (Invitrogen; SV40 and JCV only; used in section 4.0) or the pBabe-Puro 
retrovirus vector modified to work with the Gateway cloning system (Invitrogen; SV40, BKV, 
JCV, and LPV, used in section 3.0). pPyLT was received from Fried and contains the MuPyV 
LT cDNA. The LT cDNA was digested out of the original plasmid and ligated into the pLenti6.3 
vector. 
 Truncations of viral ERs were produced by PCR. Primers were designed to amplify 
desired regions of each ER (Table 3). Then, each truncated ER fragment was cloned into the 
pLenti6.3-TOPO vector. An artificial Kozak sequence (ACC) was included before the start 
codon of all constructs to ensure efficient translation. The truncated constructs required the 
addition of a stop codon immediately after the sequence. The full length early region includes 
nucleotides 2691-5163 of SV40, 2603-5013 of JCV, 2722-5153 of BKV, and 2822-5270 of LPV. 
N-terminal fragments contain nucleotides 4410-5163 of SV40, 4259-5013 of JCV, 4396-5153 of 
BKV, 4316-5270 of LPV. Murine polyomavirus N200 fragment was made from pPyLT 
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mentioned above, therefore this construct contained nucleotides 175-411 joined to 797-2917. 
VHR-truncated early regions contain nucleotides 2943-5163 of SV40 and 2792-5013 of JCV. 
2.2 CELL CULTURE, TRANSFECTIONS, AND TRANSDUCTIONS 
Harvest of murine embryonic fibroblasts (MEFs) from FVB mice was performed as previously 
reported (Markovics et al., 2005). MEFs were maintained in DMEM medium supplemented with 
10% FBS, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37°C in 5% CO2. Where 
indicated, confluent MEFs were treated with a final concentration of 1 µg/ml of doxorubicin 
(Adriamycin, Sigma) in growth medium for 9 hours. The cells were then trypsinized and 
harvested for protein or RNA extraction as in sections 2.3 and 2.5. 
 MEF pools described in section 3.0 were created by transduction. Modified lentivirus 
vector particles harboring the various T antigen constructs were made according to the 
Invitrogen Virapower protocol. For pBabePuro constructs containing early region sequences, 
phoenix-eco cells in 10-cm tissue culture dishes were transfected with a mixture of 12 μg of 
pBabePuro-T DNA and 18 μl of Fugene6 or FugeneHD (Promega) in DMEM to a total volume 
of 600 μl. Mixing was performed according to the Fugene instructions. Virus-containing medium 
was collect 48-72 hrs later. The collection was spun at 2000xg for 15 min at 4 °C to remove 
cellular debris. Fresh, undiluted medium containing virus was placed directly onto MEFs and 
incubated for 24hrs in the presence of polybrene. Virus-medium was removed and replaced with 
fresh growth medium. MEFs were allowed to recover for 48 hrs before selection with 2 μg/ml 
Puromycin or 2 ug/ml Blasticidin. Cells were kept under selection until all mock-transfected 
MEFs died. All surviving cells from an individual transduction were pooled. 
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For pools described in section 4.0, T antigen plasmids were transfected into MEFs in 6-
well culture plates using Fugene6 (Promega) following the manufacturer’s protocol with 
minimal modifications. A ratio of 1 μg plasmid to 3 μl Fugene was used. Forty-eight hours after 
transfection, cells were transferred to 10-cm tissue culture dishes and allowed to recover 
overnight before starting selection with 2 μg/ml blasticidin (Invitrogen). Cells were kept under 
selection until all mock-transfected MEFs died. All surviving cells from an individual 
transfection were pooled, and three independent pools were generated for each plasmid 
construct. All experiments were performed with cells between passages 3 and 10. 
2.3 WESTERN BLOT AND IMMUNOPRECIPITATION 
All cells were collected at 2 days post-confluence and lysed with either RIPA buffer (50 mM 
Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Na Deoxycholate, 1% Triton X-100, 1 mM EDTA) for 
western blot analysis, or buffer containing 50 mM Hepes pH 7.9; 0.4M KCl; 0.5 mM EDTA; 
0.1% NP40 and 10% glycerol for immunoprecipitation assays. Lysis and subsequent procedures 
were performed in the presence of protease and phosphatase inhibitors (1X Calbiochem protease 
inhibitor cocktail I, 1 mM pepstatin, 10 μM leupeptin, 1 mM Na3VO4, 1 mM NaF). Clarified 
lysates were collected and protein concentration was assessed by the Bio-Rad protein 
microassay. 
For western blots, equal amounts of total protein were mixed with Laemmli buffer and 
heated at 95°C for 5 minutes to denature proteins. We routinely separated 15-30 μg of denatured 
protein by SDS-PAGE, then transferred proteins to PVDF, and performed western blot with 
indicated antibodies. T antigen specific antibodies are as follows: anti-JCV T antigen specific 
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monoclonals PAb 962 (Tevethia et al., 1992) and PAb 2003 (Bollag et al., 2000) (both received 
from Richard Frisque); anti-SV40 T antigen monoclonal antibodies PAb 416 and PAb 419 
(Harlow et al., 1981); anti-MuPyV T antigen PN116 (Holman et al., 1994); anti-HuPyV10 
received from Chris Buck, unpublished. Epitopes of each antibody and their reactivities to T 
antigens of different polyomaviruses are listed in Table 3.  
The following antibodies were used to detect cellular proteins: p130 C-20 (SantaCruz sc-
317x), p53 (PAb 421 (Harlow et al., 1981) or HRP-conjugated anti-p53 from  Santa Cruz), S15 
phospho-p53 (Cell Signaling 9284S), K379 acetyl-p53 (Cell Signaling 2570S), GAPDH (US 
Biological G8140-11). 
 For immunoprecipitation assays, 25 μl of Protein G Dynabeads magnetic particles (Life 
Sciences) were first incubated for an hour at 4 °C with 50 μl of anti-p53 PAb421 hybridoma 
supernatant, supplemented with PBS to achieve a final volume of 250 μl. Equivalent amounts of 
total protein extracts (50-100 μg) were then added to the different reactions and allowed to mix 
for 4 hours at 4 °C. Pellets containing the immunoprecipitated complexes were retrieved with a 
magnetic stand and washed four times at 4 °C with PBS plus protease inhibitors. Protein 
complexes were eluted from the magnetic beads by incubation with 20 μl 0.1 M glycine pH 2.8 
for 10 minutes at room temperature, and were subsequently neutralized with 2 μl 1M Tris-HCl 
pH 8.0 and prepared for SDS-PAGE. T antigen and p53 proteins were detected by western blot 
as indicated. 
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2.4 TRANSFORMATION ASSAYS 
2.4.1 Immortalization 
Immortalization involves extending the lifespan of primary cells in culture. Primary cells are 
those that are taken directly from normal tissue and selected for growth in culture. They have a 
limited capacity for proliferation, sometimes lasting only a few passages before growth arresting. 
Mutations or viral gene products can be expressed and tested for the ability to prolong the life 
expectancy of primary cells. 
Pools of MEFs that expressed a T antigen construct were passaged consecutively at either 
a 1:10 or 1:5 dilution. Normal MEFs were passaged at the same time, but these cells cease to 
proliferate between passages 4 and 6. MEFs expressing T antigen that survived 10 or more 
passages were considered immortal.   
2.4.2 MEF survival assay 
MEFs were plated in a 96-well plate at 1000 cells per well in a total volume of 100μl and 
incubated overnight at 37 °C. The cells were then transduced with 100μl of the appropriate 
retrovirus or lentivirus vector along with 12 ug/ml Polybrene (Invitrogen). Mock transduced cells 
were treated with Polybrene only, and all subsequent steps were performed the same as virus 
treated cells. Twenty-four hours later the virus was removed, replaced with normal growth 
medium, and the cells were allowed to recover for another 48 hrs. Cells from each well were 
trypsinized and transferred to individual 10cm tissue culture dishes with 10ml of normal growth 
medium. Cells were fed every four days. The plates were fixed and stained when dense colonies 
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were observed or after 18 days in culture. Cells were fixed with a solution of 10% methanol and 
10% acetic acid in H2O for 20 min. Colonies were visualized by staining with 5 ml of 0.4% 
crystal violet in 20% ethanol for 1-2 hrs then washed with tap water at least twice to remove 
excess stain. 
2.4.3 Growth in low serum 
3x104 cells were seeded onto 6-well tissue culture plates in DMEM + 10% FBS. To produce low 
serum conditions, the medium was replaced six hours later with DMEM + 1% FBS, after 
washing the cells once with PBS. Cells for both low and normal (10%) serum assays were 
incubated overnight before counting the first time point. This was considered time zero. Cells 
from two wells were counted with a hemacytometer and averaged every day (normal growth) or 
every other day (low serum growth) for up to 12 days.  
The average number of cells counted (y-axis) at each time point (x-axis) was plotted on a 
graph and the doubling time was calculated using two time points within the exponential growth 
phase according to the equation: 
 
Doubling time = T ln2 / ln(X2/X1) 
 
where T is the incubation time in hours, X2 is the number of cells from the later time point, and 
X1 is the number of cells from the earlier time point. Doubling time was divided by 24 to 
convert the value into doublings per day. 
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For experiments in Section 3.0, pools expressing T antigen N-terminal fragments or 
normal MEFs were tested 2-4 times. Each independent experiment was plotted on a graph of log2 
of the cell number vs. time. 
For experiments in Section 4.0, each pool expressing the same early region construct was 
considered a biological replicate. Wild-type MEFs were independently tested twice, constituting 
technical replicates. The doubling times from all replicates were averaged and the standard 
deviation was calculated using the Excel function “STDEV.S”. The standard error of the mean 
was derived by dividing the standard deviation by the square root of the number of replicates. 
2.4.4 Dense focus formation 
A total of 3x105 normal MEFs were plated onto a 10cm tissue culture dish and briefly incubated 
(less than 2 hours) while T antigen expressing MEFs were trypsinized and counted. One 
thousand T antigen-MEFs were then added to the normal MEFs, and gentle rocking was used to 
get an even distribution across the dish. Cells were incubated for up to 16 days, then fixed with a 
solution of 10% methanol and 10% acetic acid in H2O for 20 min. Dense foci were visualized by 
staining with ~5 ml of 0.4% crystal violet in 20% ethanol for 1-2 hrs then washed with tap water 
at least twice to remove excess stain. Duplicate plates were prepared for each cell type per 
experiment. At least two experiments were performed.  
2.4.5 Anchorage independence assay 
1.6x104 cells were suspended in 0.3% agarose (Invitrogen Ultrapure) in growth medium on top 
of a 0.5% agarose medium base layer in 35-mm tissue culture dishes, as previously reported (Sun 
 43 
and Taneja, 2007). All experiments were performed in duplicate. Colony formation was 
observed after 21 days of incubation at 37 °C. 
For experiments in Section 3.0, photographs of colonies or individual cells were taken at 
the same magnification. For experiments in Section 4.0, the area of all single and multi- cell 
events was measured. The area cut-off value chosen (1165 μm2) to define a colony allowed for 
1% or less anchorage independent (AI) colonies in the control MEF populations. The number of 
colonies from each plate was divided by the total number of cellular events to obtain the 
percentage of anchorage independent colonies formed. Each pool was tested twice and the 
percentages of AI colonies from both assays were averaged. Pools expressing the same early 
region construct were considered biological replicates and the percentages of AI colonies from 
all three pools were averaged. One of the JCV.ER-expressing pools (pool C) was deemed an 
outlier as it did not accurately represent the behavior of JCV early region as seen in pools A and 
B, or as previously reported (Bollag et al., 1989; Hayashi et al., 2001; Trowbridge and Frisque, 
1993). It was, therefore, excluded from the analysis and the percentages of AI colonies from the 
remaining two JCV.ER-expressing pools were averaged. The standard error of the mean was 
calculated as for the low serum growth assay. 
2.5 REVERSE-TRANSCRIPTION AND REAL-TIME PCR 
Standard techniques were used to extract total RNA from cells (Qiagen RNeasy Kit including the 
on-column DNA digestion with the Qiagen RNAse-free DNase set), and to synthesize cDNA 
(Saenz-Robles et al., 2007). The type and level of transcript species produced by different T 
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antigen constructs were monitored with reverse-transcription PCR. Levels of E2F-regulated 
genes were evaluated using either reverse-transcription or real-time PCR methods.  
Primers used for all RT-PCRs are listed in Table 4. Amplification of all possible T 
antigen specific cDNAs by reverse transcription PCR was performed using primers A and B 
(SV40), E and B (JCV), or  H and B (BKV) from 1 μg of total cDNA with the Roche Expand 
Long Template PCR system, using buffer 1 with the following cycling parameters: 94°C for 3 
min, then 30 cycles of 94°C 30 sec, 54°C (SV40 & BKV) or 55°C (JCV) for 30 sec, 68°C 3 min, 
a final extension was performed at 68°C for 10 min. Specific E2F-target gene cDNAs or LT and 
sT cDNAs (primers: SV40 C+D, JCV F+G) were amplified from equal amounts of total cellular 
cDNA by PCR using GoTaq master mix (Promega) and the corresponding primers as previously 
reported (Rathi et al., 2009). Annealing temperatures were as follows: Pcna 55°C, Dhfr 55°C, 
Mcm3 55°C, Cdc6 55°C, Rpl5 56°C, T antigen (C+D) and (F+G) 55°C. PCR products were 
separated on a 2% agarose gel in 1x Tris-acetate-EDTA and stained with ethidium bromide. 
Images were captured with a Fujifilm LAS-3000 imager. 
 Real time PCR was performed on 1 μg of total cDNA was mixed with gene specific 
primers (Table 4) and SYBR Green real-time PCR master mix. Amplification was performed on 
an Applied Biosystems 7300 cycler using the default conditions suggested by the manufacturer. 
 
  
 45 
  
Table 1. Polyomavirus sequences in this study 
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Table 2. Primers for PCR cloning of T antigen early regions and 
mutants 
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Table 3. T antigen monoclonal mouse antibody epitopes and reactivity. 
+, T antigen species is recognized. - , T antigen not recognized. Some antibodies were 
not tested for reactivity to certain T antigen proteins and are represented by a blank 
space. Some of the reactivity information listed is taken from previous publications. 
SV40 (Bollag et al., 2000) . JCV (Bollag et al., 2000). MuPyV (Holman et al., 1994).  
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Table 4. Primers for reverse-transcription and real-time PCR 
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3.0  LARGE T ANTIGEN FRAGMENTS CONTAINING THE J DOMAIN AND 
LINKER REGION FROM SEVERAL POLYOMAVIRUSES INCREASE THE 
LIFESPAN OF MEFS, BUT VARY IN TRANSFORMATION  
3.1 INTRODUCTION 
SV40 large T antigen has at least three distinct elements that contribute to transformation of 
cultured cells: the J domain; the LxCxE motif; and the p53 binding region (Zhu et al., 1992). 
Truncation analysis has revealed that fragments of SV40 LT that express the J domain and 
various lengths of the linker region containing the LxCxE motif allow certain transformation 
phenotypes independently of the p53 binding C-terminus region in rodent cells. An SV40 LT 
fragment containing amino acids 1-147 (T147) extended the life of primary mouse cells in 
culture, but could not immortalize (Tevethia et al., 1998). T147 is also sufficient to cooperate 
with oncogenic Ras to transform primary rat cells (Beachy et al., 2002; Cavender et al., 1995). 
Transformation of established cell lines as determined by dense focus formation occurred with 
similar LT fragments, although the efficiency of transformation was lower than full length LT 
(Sachsenmeier and Pipas, 2001; Srinivasan et al., 1989). Finally, anchorage independence was 
not achieved by N-terminal fragments in primary mouse cells (Thompson et al., 1990).    
The transformation phenotypes described above are consistent with the N-terminal 
fragments’ ability to inhibit the pRB family of proteins to induce cell proliferation, and inability 
to control growth suppression eventually brought on by p53. Although many large T antigens 
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have been shown to bind pRB through the LxCXE motif (Dyson et al., 1990) and contain a J 
domain, it remained to be seen if comparable short N-terminal fragments of other transforming 
polyomavirus LTs behaved similarly to SV40.  
A phylogenetic tree made from an alignment of the large T antigen (LT) protein from 
five transforming polyomaviruses gives an idea of the extent of variation in sequence of the LT 
(Figure 9 A). SV40, BKV and JCV LTs are very closely related, while LPV and Murine LTs are 
more distantly related from each other and from the SV40/BKV/JCV cluster. This clustering also 
closely mirrors the transforming properties of the LTs (Figure 9 B). SV40, BKV, and JCV LTs 
are capable of transforming rodent cells on their own, and they bind to both pRB and p53. It has 
been shown previously that MuPyV inhibits pRB proteins, but does not bind to p53, which 
contributes to its inability to fully transform cultured cells. Large T antigen of LPV has been 
shown to bind to pRB; however, there are mixed reports about its ability to bind to and inhibit 
p53 (Kang and Folk, 1992; Symonds et al., 1991).  
One of the regions of LPV and MuPyV that is least conserved with SV40 LT is the linker 
region between the J domain and OBD (Figure 9 C), which is known to bind many cellular 
proteins in SV40 LT. Despite the overall sequence disparity, contained within all of the N-
terminal linker regions are motifs for binding pRB (LxCxE), Hsc70 (HPDKGG), and nuclear 
localization (NLS) (Figure 10). In addition, SV40, BKV, JCV, and LPV have a motif shown in 
SV40 to be required for binding to the cellular protein Bub1 (WxxWW) (Cotsiki et al., 2004); 
however, this interaction has not been tested in other T antigens. SV40 N-terminal linker region 
can also bind to Cul7 (Figure 10). The binding sequence found in SV40 LT is not well conserved 
in the other polyomaviruses, suggesting that Cul7 binding may not occur with other LTs. 
Although the Bub1 and Cul7 interactions with full length SV40 LT contribute to transformation 
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(Hartmann et al., 2014; Kasper et al., 2005), the significance of these interactions with the SV40 
N-terminal fragment have not been established. Finally, the linker of LPV and MuPyV is longer 
than that of SV40, BKV, or JCV (Figure 10), insinuating that more cellular proteins could bind 
to this region and perhaps effect transformation. 
The presence of pRB family binding and inhibitory elements suggests that transformation 
phenotypes that require only this activity of LT would be conserved for each of the T antigens. 
However, for LPV and MuPyV, the variation in sequence of the J domain and linker region and 
in the length of the linker region compared to SV40, might allow for other interactions that affect 
transformation. To test this hypothesis, both the early regions and N-terminal fragments of LT (J 
domain and linker region only) for each virus were expressed in primary mouse cells and 
compared in parallel for the ability to transform in several assays. Each construct was also tested 
for its ability to affect the pRB pathway.   
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SV40 BKV JCV LPV MuPyV
AA Length 708 695 688 697 782
J domain 100 82 82 38 34
J domain + linker 100 79 81 32 18
OBD 100 83 80 40 45
Helicase 100 77 75 47 48
VHR 100 30 39 - -
J domain 34 33 35 38 100
J domain + linker 18 18 19 24 100
OBD 45 42 41 48 100
Helicase 48 47 46 50 100
% Identity to SV40
% Identity to MuPyV
Large T antigen 
SV40 LT  
Chaperone and 
pRB binding 
Helicase and 
p53 binding 
MuPyV LT 
Chaperone and 
pRB binding Helicase 
B) A) 
C) 
 BKV
 JCV
 SV40
 LPV
 MuPyV
0.1
 
Figure 9. Comparison of sequence and structure of polyomavirus large T antigen proteins. 
A) SV40, BKV, JCV, LPV, and MuPyV LT proteins were aligned and a phylogenetic tree was created 
using the maximum likelihood method. The tree shows 3 main branches. SV40, BKV, and JCV are 
very closely related. Murine PyV LT is the most distantly related to SV40 LT, while LPV LT makes up 
a third branch that is distantly related to both SV40 and MuPyV LTs. B) SV40 and MuPyV large T 
antigen domain structure. Both LTs share a similar distinct domain structure and contain motifs needed 
to bind and inhibit the pRB family of proteins (HPDKGG and LxCxE). Several important differences 
are highlighted. The linker region between the J domain and OBD is longer in MuPyV LT. SV40 LT 
contains a C-terminal tail known as the variable linker and host range region (VHR), and  it can bind  
to the p53 tumor suppressor through its ATPase domain. C) Each domain of LT was aligned to either 
SV40 or MuPyV LT and a percent identity of amino acids was calculated.  
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Figure 10. Sequence analysis of N-terminal fragments containing the J domain and linker 
region of five T antigen proteins. 
Alignment of N-terminal fragment sequences was performed with MUSCLE. Amino acids are 
colored according to the following chemical properties: red are small and/or hydrophobic, blue 
are acidic residues, pink are basic residues, and green includes hydrophilic residues and  glycine. 
Yellow highlight regions are well known cellular protein binding motifs. Vertical black lines 
denote the boundary between the J domain and linker region. Regions highlighted in blue are 
important for SV40 binding to Cul7. 
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3.2 RESULTS 
3.2.1 Construction and expression of T antigen early regions and fragments containing 
the J domain and linker regions.  
Both the early region (ER) and fragments containing the J domain and linker region of each 
polyomavirus were cloned into retrovirus or lentivirus vectors. Early regions have the potential 
to express all alternatively spliced forms of T antigen, including the LT and sT proteins. In the 
case of MuPyV, the LT cDNA was cloned instead of the entire early region. This construct 
cannot produce the middle T or small T, and it acts as a negative control for transformation 
assays. The N-terminal fragments contained the entire amino acid sequence from the initial 
methionine to the last amino acid before the OBD. Abbreviations for N-terminal fragments are as 
follows: polyomavirus initials.N(# of amino acids from LT). For example, the SV40 N terminal 
fragment is SV.N136, since the J domain and linker region comprise the first 136 main acids of 
SV40 LT.  
Primary murine embryonic fibroblasts were transduced with one of the viral vectors and 
selected for integration with the appropriate antibiotic. For early region constructs, two 
independent pools were created but only one pool for each construct is presented, however 
similar results were seen with both pools. Only one pool for each N-terminal fragment was 
created.      
Expression of T antigen proteins was evaluated by western blot in pooled cells that 
survived antibiotic selection (Figure 11). Due to the variance in amino acid sequence, antibodies 
created against four polyomavirus T antigens were used to detect the different T antigen proteins. 
All of the antibodies used have epitopes within the J domain or linker region, thus they should be 
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able to detect full length and N-terminal fragments (Table 3). It was not known if any of the 
antibodies would cross react with LPV T antigens.  
The SV40 antibodies PAb416 and PAb419 (Table 3) successfully identified LT 
expression in MEFs with SV40.ER and JCV.ER constructs and the LT N-terminal fragment in 
MEFs with SV.N136, BK.N138, and JC.N137 constructs (Figure 11, top left). Small T antigen 
was not seen in either SV40.ER or SV.N136 MEFs (data not shown). PAb 416/419 did not cross-
react with LPV or MuPyV T antigens. 
Since the SV40-specific antibodies did not detect BKV LT in BKV.ER samples nor did 
they have the ability to cross-react with the small T antigens of BKV and JCV, we employed a 
set of JCV-specific monolconals, 962 and 2003 (Table 3). These antibodies did not identify 
proteins from either BKV.ER or BK.N138 samples; however, they did detect JCV T antigen 
proteins (Figure 11, top right). With these antibodies, it was clear that the JCV.ER MEFs were 
expressing LT protein as well as other smaller protein/s between 20 and 25 kD. At this size, this 
band could represent JCV sT (~ 21 kD), T’136 (~ 20 kD), or T’165 (~ 25 kD) proteins. A third 
JCV T’ protein, T’135 (~ 17 kD), was not detected. PAb 962 + 2003 also confirmed expression 
of the JCV LT N-terminal fragment. 
Murine PyV-specific antibody, PAb 116, showed expression of MuPyV LT as well as the 
N-terminal fragment in MEFs (Figure 11, bottom left). This antibody did not cross-react with 
BKV or LPV T antigens (data not shown). An antibody directed against HuPyV10 (a.k.a. 
MWPyV), Xt7, was able to detect purified LPV T antigen protein (data not shown). Furthermore, 
the LPV LT and N-terminal fragment from MEF cell lysates were recognized by this antibody 
(Figure 11, bottom middle). A doublet appeared in the LP.N200 sample. I hypothesize that this 
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doublet represents post-translationally modified forms of the LT N-terminal fragment since they 
are so close in size. 
BKV T antigen protein was not observed in BKV.ER MEFs. There were at least two 
possibilities for this: 1) BKV transcript was not produced due to some unknown reason, or 2) 
BKV protein was being expressed but at very low levels that could not be seen by western blot. 
To address the first possibility, reverse-transcription PCR was performed on total RNA isolated 
from BKV.ER MEFs using primers that would allow for detection of all alternatively spliced 
transcripts (Figure 12). Three main transcripts were detected: LT, mini T, and a transcript that 
did not correspond to the size of any known T antigen mRNAs. Interestingly, LT transcript was 
in the lowest abundance, while the mystery transcript was the highest. Based on the size of the 
mystery transcript, this transcript is predicted to be spliced at the second intron but not the first 
intron (see diagram in Figure 12). Detection of LT transcript implies a post-transcriptional step 
that is effecting the expression of BKV LT protein.     
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Figure 11. T antigen protein expression in MEFs. 
Proteins from pools with T antigen early region or N-terminal fragment constructs were separated by 
SDS-PAGE and visualized by western blot. Several antibodies directed against T antigen proteins from 
different polyomaviruses were used to detect T antigen protein expression. A molecular size marker in 
kiloDaltons (kD) is indicated to the right of each blot. Large T antigens run between 100 and 75 kD. N-
terminal fragments of the T antigens run between 15 and 37 kD. In JCV.ER samples, PAb 962+2003 
detected a smaller T antigen between 20 and 25 kD that could be sT or the T’136 protein. T antigen 
protein was not seen by western blot in BKV.ER MEFs. 
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Figure 12. BKV early region transcript expression 
in MEFs. 
T antigen mRNAs were amplified by RT-PCR. Primers 
surrounding the entire early region were used to capture 
all alternatively spliced transcripts. Bands corresponding 
to the large T antigen (LT) and mini T proteins are 
indicated. A diagram of the mRNAs for each band is 
shown at the right: horizontal lines indicate exons, while 
carets represent introns that have been removed by 
splicing. The band at approximately 1000 bp does not 
correspond to a known BKV T antigen product. A 
possible transcript based on the size of the band is shown.    
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3.2.2 N-terminal fragments of five different T antigens are sufficient to extend the life of 
MEFs 
Once expression of T antigen was established, we set out to determine if the early regions and N-
terminal fragments could extend the life of MEFs similar to SV40.N136. Two experimental 
approaches were utilized. In the first, the MEF pools described above were subjected to 
consecutive passaging in culture alongside normal MEFs. Table 5 lists the number of passages 
each cell pool survived. Normal MEFs were passaged five times before they became growth 
arrested and eventually began to die. All ER/LT expressing MEFs were passaged beyond 10 
times with no signs of growth arrest. MEFs with the N-terminal fragments survived a 
consecutive 10 passages before the experiment was stopped. 
 The second method used is referred to as the MEF survival assay (diagrammed in Figure 
13 A). In this assay, ER or N-terminal fragment constructs were introduced into a small number 
of MEFs by retrovirus or lentivirus transduction in 96-well plates. After a recovery period, 
transduced cells were transferred to a 10cm dish effectively creating an extremely low density 
environment. Colonies of surviving cells were visualized by staining with crystal violet. Within a 
few days, normal MEFs cease proliferation and take on a large flat morphology and staining is 
very light and sparse (Figure 13 B and C). Control vectors containing LacZ or Cre recombinase 
genes did not increase the ability of MEFs to survive, whereas all T antigen constructs allowed 
MEF colony formation (Table 6; Figure 13 B). It was clear that SV40.ER produced the densest 
and most numerous colonies of all constructs tested, while MuPyV.LT showed the weakest 
staining and least number of colonies over several experiments (Figure 13 B; Table 6). Although 
all N-terminal fragments permitted colony formation, there was an unmistakable decrease in the 
number of colonies produced compared to the full length counterparts (Table 6). Regardless of 
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the number of colonies, the morphology of the cells within colonies was clearly transformed 
compared to control MEFs (Figure 13 C). 
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Table 5. Extension of life of MEFs by 
polyomavirus T antigen constructs 
a Early region and MuPyV.LT expressing MEFs were 
carried beyond 10 passages. 
b MEFs expressing N-terminal fragments were only carried 
for 10 consecutive passages and then the experiment was 
stopped.  
c  At 5 passages, normal MEFs became flat and enlarged 
and stopped proliferating. 
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Figure 13. T antigen full length and N-terminus fragments extend the life of MEFs in the MEF 
survival assay. 
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A) Steps in the MEF survival assay. One thousand normal MEFs are plated into each well of a 96 
well plate and allowed to incubate overnight. These cells are then transduced with viral vectors 
containing one of the polyomavirus genes or gene fragments. Medium containing viral vectors is 
removed 24 hours later, and the cells are allowed to recover for 48 hours. Cells from one well are 
trypsinized and transferred to a 10cm tissue culture dish. The highly diluted cells are incubated for 
up to 18 days, at which time they are fixed and stained to visualize cell colonies. B) Colony 
formation produced by different T antigen constructs. Mock transduction and transduction with 
vectors containing control genes (LacZ, Cre) show very few light staining colonies, while T 
antigen expressing MEFs display several dark staining colonies. C) Images of cells from colonies 
of MEFs. Each image was taken at the same magnification with a camera attached to a bright field 
microscope. Note the distinct difference in morphology of cells transduced with T antigens 
compared to control plasmids or mock. 
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Table 6. Number of colonies produced in the MEF Survival Assay 
TMTC, too many to count. 
(-), indicates that gene was not tested during the particular experiment. 
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3.2.3 Polyomavirus early regions induce transformation of MEFs 
We investigated the ability of the T antigen constructs to stimulate three distinct transformation 
phenotypes in MEFs: growth in low serum, loss of contact-inhibited growth (dense focus assay), 
and anchorage independent growth (soft agar assay). SV40 early region has been shown to cause 
all three of these phenotypes in rodent cells. On the other hand, it has been well documented that 
MuPyV LT alone cannot induce loss of contact-inhibited growth or anchorage independent 
growth, but does allow growth of cells in reduced serum conditions (Rassoulzadegan et al., 
1982). SV40.ER and MuPyV.LT MEFs behaved as expected in the low serum growth, dense 
focus formation, and soft agar assays (Figures 14, 15, and 16). JCV, BKV, and LPV early 
regions were also able to transform MEFs, similar to SV40.ER, in all assays. 
3.2.4 Most N-terminal fragments of T antigen are sufficient for growth in low serum, but 
vary in dense focus formation 
The N-terminal fragments showed variable abilities to transform cells in both low serum and 
dense focus assays. Cells expressing SV.N136, BK.N138, JC.N137, and LP.N200 went through 
at least two population doublings when cultured in low serum conditions, whereas normal MEFs 
could barely reach one population doubling (Figure 14). Also, under low serum conditions, the 
cells with N-terminal fragments showed a lower cell density at the plateau phase compared to the 
same cells in normal serum. This lower plateau was not seen in cells expressing the early region. 
During the exponential phase of growth, cells with SV.N136, BK.N138, JC.N137, or LP.N200 
constructs grew at equivalent or slightly slower rates in low serum compared to growth in normal 
serum (Table 7).  
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Mu.N290 MEFs doubled only once and then began to decline while in low serum 
conditions, similar to normal MEFs (Figure 14; Table 7). This was initially unexpected since the 
MuPyV LT had been shown to allow growth in nutrient deprived conditions; however, the p130 
protein levels (used as an indicator of T antigen interaction with pRB proteins) in Mu.N290 cells 
remained much higher than any of the other T-antigen cell pools (Figure 17 A). Thus, the pRB 
interaction with Mu.N290 may be impaired, but further tests are needed to confirm this 
hypothesis. 
 Normal MEFs will cease to proliferate when in a crowded environment, forming a 
monolayer of cells. This is known as contact-inhibition. Cells that loose this ability continue to 
grow vertically above the monolayer creating clusters of cells called dense foci. It has been 
shown previously that SV.N136 cannot induce loss of contact inhibition in primary-like rodent 
cells (Sachsenmeier and Pipas, 2001). Accordingly, we did not find any foci formed with 
SV.N136 MEFs (Figure 15). LP.N200 and Mu.N290 MEFs also failed to form dense foci. 
Interestingly, BK.N138 and JC.N137 MEFs formed foci; however, they were not as dense as the 
foci seen in BKV.ER or JCV.ER MEFs.   
3.2.5 The N-terminal fragment of T antigens cannot induce anchorage independent 
growth in MEFs 
Turning a normally adherent cell into one that can grow in an anchorage independent 
environment is considered one of the most stringent transformations. While the SV40, BKV, 
JCV, and LPV early regions were all able to form colonies while suspended in soft agar, this was 
not the case with any of the N-terminal fragments (Figure 16). MEFs expressing the N-terminal 
fragments remained as single cells for the entire three week incubation in soft agar.  
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Table 7. Doubling time of T 
antigen expressing MEFs in varying 
serum conditions. 
Cells were grown as described in 
figure 14. Doubling times were 
calculated from data points within the 
exponential phase of growth. 
Doubling times from at least two 
experiments were averaged and the 
standard error of the mean was 
determined.    
 69 
 
  
Figure 15. Dense focus formation by T antigen expressing MEFs. 
One thousand T antigen expressing MEFs were seeded onto a monolayer of normal MEFs. After 
incubation for up to fifteen days, cells were fixed and stained to visualize foci. The mock is a MEF 
monolayer with no cells seeded that was stained after 15 days. Pictures are representative of results 
seen in at least two experiments. 
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Figure 16. Anchorage independent transformation is lost in 
cells expressing T antigen N-terminal fragments. 
Cells were suspended in soft agar medium and incubated for 21 
days. Those that were able to proliferate formed anchorage 
independent colonies (black arrows). Cells that did not attain 
anchorage independent transformation remained as single cells. 
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3.2.6 T antigen N-terminal fragments show minimal activation of E2F-target genes even 
though interaction with pRB proteins are retained  
Both early region and N-terminal fragments were assessed for the ability to interfere with the 
pRB pathway, since this function of T antigen is known to be required for transformation. We 
examined the pathway at two steps: 1) interference with p130 protein, and 2) activation of 
common E2F regulated genes.  
p130 is a member of the pRB family of proteins that forms complexes with E2F4/5 
transcription factors. The complex sits at the promoter of cell cycle genes inhibiting their 
expression. Large T antigen binds p130 through the LxCxE motif, and the breaking of the 
inhibitory complex requires the J domain. In addition, cells expressing SV40 LT display 
decreased levels of p130 protein (Stubdal et al., 1997). MEFs expressing the polyomavirus early 
regions and MuPyV LT showed decreased levels of p130 protein compared to normal MEFs, 
suggesting a functional interaction with LT (Figure 17 A). Cells expressing N-terminal 
fragments of all T antigens also had lower levels of p130; however, Mu.N290 MEFs did not 
show as great of a decrease as the other N-terminal fragments (Figure 17 A). 
Large T antigen also disrupts a complex of pRB and E2F1/2/3. In this complex, pRB is 
preventing the activator E2Fs from binding to cell cycle gene promoters and triggering 
transcription. When LT breaks this complex, these E2Fs go on to activate expression of genes 
required to induce the S phase. We monitored the expression of a set of canonical E2F target 
genes in MEFs expressing the polyomavirus early region or N-terminal fragments by real-time 
PCR. ER and MuPyV.LT expressing MEFs induced transcription of E2F target genes at least 5-
fold over the level in normal MEFs (Figure 17 B, top). It was expected that all of the N-terminal 
fragments would show similar induction levels of E2F target genes; however, only SV.N136 and 
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JC.N137 cells showed at least a 3-fold induction of all genes tested (Figure 17 B, bottom). For 
BK.N138 cells, two genes showed a 2-fold increase and three others were at equivalent levels or 
only 1.5-fold higher than normal MEFs. In cells expressing LP.N200, only one gene tested was 
expressed above the 2-fold induction mark. Mu.N290 cells were not included in this experiment.  
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Figure 17. Downstream effects of binding to pRB family proteins are altered in cells expressing N-
terminal fragments of T antigen.  
A) Steady-state levels of p130 protein determined by western blot. B) Expression of several common E2F 
controlled genes. Real-time PCR using primers specific for the indicated cellular genes was performed on 
total cDNA from the specified cells. Fold increase of transcript level over normal MEFs is shown. 
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3.3 DISCUSSION 
To understand if similarities or differences in amino acid sequence of the J domain and linker 
regions of the LTs of transforming polyomaviruses correlated with differences in transformation 
phenotype, four polyomavirus full length early regions and five N-terminal fragments were 
compared in several transformation assays. Murine PyV LT served as a negative control, since it 
is known that the middle T is required for full transformation. As suggested by previous reports 
using immortal and primary rodent cells, we found that all early regions and MuPyV LT could 
extend the life of primary MEFs in two different assays (Bollag et al., 1989; Cavender et al., 
1995; Rassoulzadegan et al., 1983; Symonds et al., 1991). Furthermore, SV40, BKV, JCV, and 
LPV early regions efficiently transformed the cells in all assays, as expected.  
Large T antigen protein was expressed in all early region expressing MEFs, except for 
BKV. Yet, BKV LT cDNA was seen by RT-PCR. The plasmid used for transduction was 
verified by sequencing and no mutations were found (data not shown). It is possible that the 
large T antigen transcript is not translated for unknown reasons. A more likely explanation, 
however, is that the level of BKV LT protein is too low for detection by Western blot. Other 
reports have also seen very low expression of BKV LT (Bollag et al., 1989; Harris et al., 1996). 
Preliminary experiments where BKV.ER MEFs were treated with MG132 did not show an 
increase in BKV LT protein expression, which suggests that LT is not degraded by the 
proteasome (data not shown). Still, other mechanisms of protein degradation that are known to 
regulate the level of cellular proteins (e.g. autophagy) cannot be ruled out. Further 
experimentation would be needed to determine the reason for the inability to detect BKV LT 
protein. There is most likely some LT present, as the ability to transform was retained in two 
independent cell pools made with the same BKV.ER construct. 
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A few common features of transformation by the N-terminal fragments were revealed in 
this study, but this data should be considered carefully since only one cell pool for each N-
terminal fragment was tested. First, each T antigen N-terminal fragment increased the lifespan of 
primary MEFs; however, the lower number of surviving colonies for SV.N136, BK.N138, 
JC.N137, and LP.N200 in the MEF survival assay suggests that they were less efficient than the 
early regions. This result shows that while the J domain and linker region are sufficient, an 
activity in the C-terminus of the LTs enhances the cell’s ability to survive the stress of the MEF 
survival assay. For SV40, BKV, and JCV, this activity is most likely p53 inhibition. Indeed, for 
SV40, it has been shown that both the N- and C-terminus of LT are required to immortalize 
MEFs in cis or in trans (Tevethia et al., 1998). This may be the case for LPV as well, since I 
have seen p53 stabilization by western blot in MEFs expressing LPV.ER similar to JCV.ER (data 
not shown), but this does not determine whether LPV is directly binding to p53. 
Second, none of these fragments were capable of inducing anchorage independent growth 
of MEFs. This confirms that, alone, LT binding to pRBs and other activities of the J domain and 
linker regions are not sufficient for anchorage independent growth.  
Finally, when other transformation phenotypes were achieved with N-terminal fragments, 
there appeared to be some deficit compared to the early regions. This was apparent in the low 
serum growth assay. SV.N136, BK.N138, JC.N137, and LP.N200 allowed growth in low serum; 
however, the saturation density of these cells was noticeably reduced in low serum compared to 
cells expressing the early region counterparts. Also, in the focus formation assay, BK.N138 and 
JC.N137 MEFs formed less dense and less well-defined foci than the early region expressing 
cells.  
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Quite unexpected was the observation that BK.N138 and JC.N137 both produced dense 
foci. Based on overall amino acid conservation, BK.N138 and JC.N137 were predicted to behave 
similar to SV.N136, which does not form dense foci. Focus formation with BK.N138 and 
JC.N137 was observed in repeated assays. The foci were not as dense as the early region 
expressing cells, which could indicate an alternate mechanism for achieving loss of contact 
inhibition as compared to the full length early region. On the other hand, activities of the missing 
BKV and JCV LT domains may contribute to the robust phenotype seen when the entire early 
region is expressed. 
It will be interesting to further explore the mechanisms by which BK.N138 and JC.N137 
are inducing dense foci. A swap of the SV40 linker region with either the BKV or JCV linker 
would address the question of which domain is responsible for dense focus formation. In 
addition, the ability of BK.N138 and JC.N137 to form dense foci suggests that the features in 
common with SV40.N136 (pRB, Bub1 motifs) are not solely responsible, and that an 
unidentified activity of BK and JC in the J domain and linker regions contributes to loss of 
contact inhibition. A scan of the protein sequence alignment of BKV and JCV LT J domain and 
linker regions (Figure 18) reveals several individual amino acids that are similar in BKV and 
JCV, but differ in SV40. Sequential and combinatorial mutations of these amino acids in BKV 
and JCV to that of SV40 or another amino acid could reveal which differences are important for 
the dense focus formation by the N-terminus fragment. BKV and JCV also contain an insertion 
of the same three amino acids (KWD) in the linker region immediately preceding the LxCxE 
motif, which is not found in the SV40 linker region. Although I could not find information 
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regarding any known functions for the KWD sequence, it stands out as a potential motif and 
should be further studied to determine its role in BKV and JCV LT transformation.  
 
Another puzzling result was that even though it appeared that SV.N136, BK.N138, 
JC.N137, and LP.N200 were able to bind and affect the pRB proteins equivalent to their early 
region counterparts (as seen by a reduction of p130 steady-state levels compared to normal 
MEFs), E2F-regulated gene expression was minimal or not increased at all. While all of the early 
regions and MuPyV LT were able to induce the transcription of a few E2F target genes to at least 
5-fold over normal MEF levels, only SV.N136 and JC.N137 showed an induction of the same 
genes. BKV and LPV N-terminal fragments did not induce these E2F target genes, and other 
genes tested only showed a 2-fold induction if at all. Several possibilities could contribute to this 
result. One scenario is that for BKV, LPV, and JCV, T antigens other than LT may be required to 
inhibit all pRB family proteins. T’ proteins from JCV show different affinities for binding pRB, 
p107, or p130 (Bollag et al., 2000) – this could also be the case for BKV and LPV. Another 
possibility is that the steady state level of p130 protein is not an ideal marker to show the 
integrity of pRB binding, and that perhaps pRB and p107 binding by N-terminal fragments is not 
as efficient as with the full length LT. This could result in less E2F release and therefore less 
E2F target gene activation. Finally, gene expression is regulated by several different protein 
factors, such as chromatin remodeling proteins or multiple transcription factors (reviewed in 
Lemon and Tjian, 2000).Thus, it is possible that, in addition to activation of the E2F 
transcription factors, the full length LT activates multiple transcriptional regulation proteins that 
act on the E2F target genes that were tested, while the N-terminal fragments only activate a 
subset of these factors leading to less transcription of this set of genes. It should be noted that the 
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expression of the E2F targets that were measured did not affect the ability of the N-terminal 
fragments to extend the life of MEFs or allow proliferation under low serum conditions. 
 
The N-terminal fragment of LPV with approximately 30% identity to SV40 conferred the 
same transformation capabilities as SV40. The major role of this region for SV40 is to bind to 
pRB and Hsc70 which together release the E2Fs and induce cell proliferation. This result 
suggests that these same functions are performed by the LPV N-terminal fragment. Although 
there still may be unique cellular proteins that interact with this region of LPV, they clearly do 
not have an effect when the N-terminus fragment is expressed out of context of the full length 
LT. To address the possibility that unique portions of the LPV LT linker region may still 
contribute to transformation within the full length LT, mutations or small deletions of the region 
should be performed. There are no obvious motifs or binding sites within this region that are not 
also found in SV40 LT (Figure 10 and 18). Therefore, future studies should begin with a more in 
depth analysis of the linker region with programs that predict protein binding sites or motifs to 
identify a hierarchy of sequences to target for mutagenesis.  
Previous studies did not test the LPV LT and sT proteins for their individual abilities to 
transform cells. The experiments with LPV.ER in this section also did not separate the LT and 
sT. Further studies must investigate the contributions to transformation of cells for each protein 
individually. LPV small T antigen shares only 35% identity with SV40 sT and even less with 
MuPyV sT. However, the motifs required for binding PP2A are present indicating that LPV sT 
should bind to the cellular protein complex. The effect of binding to PP2A is more difficult to 
predict since the study of SV40 and MuPyV sT proteins, which both are required to bind to 
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PP2A for transformation, show completely different phenotypes in cells when expressed without 
the companion LT (Andrabi et al., 2011).  
 Finally, the question of whether or not LPV LT directly binds to p53 must be addressed. 
These experiments could not be performed at the start of this work because at the time we were 
not in possession of antibodies that could recognize LPV LT protein. The Xt7 antibody was 
obtained at the end of this thesis work. Immunoprecipitation (IP) conditions with Xt7 must be 
worked out to begin to determine if p53 and LPV LT associate. Though, IP experiments should 
be regarded with caution. Recently it was shown that full length MCPyV LT precipitated with 
p53, but did not bind directly as determined by FACS-FRET analysis (Borchert et al., 2014). It is 
clear that LPV early region possess potent transforming potential but the details of how the T 
antigen proteins transform remains to be determined.   
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4.0  REMOVAL OF A SMALL C-TERMINAL REGION OF JCV AND SV40 LARGE 
T ANTIGENS HAS DIFFERENTIAL EFFECTS ON TRANSFORMATION 
This work has resulted in a publication: 
Seneca, N.T., Saenz Robles, M.T., Pipas, J.M., 2014. Removal of a small C-terminal region of 
JCV and SV40 large T antigens has differential effects on transformation. Virology 468-470C, 
47-56. 
4.1 INTRODUCTION 
JCV and SV40 have been shown to cause tumors in rodent animal models and transformation of 
cells in culture, and both LTs are necessary and sometimes sufficient to induce tumorigenesis by 
targeting both pRB and p53 (Frisque et al., 2006; Pipas, 2009). In spite of this similarity, SV40 T 
antigen is more efficient than JCV T antigen in side-by-side comparisons of transformation 
ability (Bollag et al., 1989; Haggerty et al., 1989; Hayashi et al., 2001; Tavis et al., 1994; 
Trowbridge and Frisque, 1993). The reason for the difference has yet to be fully defined. A 
comparison of the amino acid sequences reveals that JCV LT is about 70% identical to SV40 LT, 
and that they are up to 80% identical in specific shared functional domains (Figure 19 A). 
Interestingly, the short C-terminal section immediately following the ATPase domain, known in 
SV40 LT as the variable linker and host range region (VHR), shows the least similarity between 
both LTs (Figure 19 A,C).  
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Previous studies have indicated that the SV40 LT VHR contributes to viral productive 
infection by allowing viral growth in different host cells (Cole and Stacy, 1987; Pipas, 1985; 
Tornow and Cole, 1983), and is required to permit growth of adenovirus in normally restrictive 
cells (Cole et al., 1979). While early studies suggested that the SV40 VHR is not required for 
immortalization or dense focus formation in rodent cells (Pipas et al., 1983; Tevethia et al., 
1988), it remained to be seen whether this region contributes to other transformation phenotypes.  
SA12, BKV and JCV polyomavirus LTs also have a VHR, but their roles in viral 
infection or transformation have not been well studied. Though these 3 VHR sequences are 
highly conserved, there is little conservation with the SV40 VHR except for a stretch of 18 
amino acids within the host range region. Within this homologous sequence there are conserved 
residues that have been shown in SV40 to be acetylated and that bind cellular proteins (Figure 19 
C) (Fine et al., 2012; Poulin and DeCaprio, 2006; Poulin et al., 2004; Welcker and Clurman, 
2005). Little examination of the JCV LT VHR region has been performed. Only one report has 
identified a cellular protein, the SCF ubiquitin ligase component β-TrCP1/2, which binds to the 
variable linker of JCV LT (Reviriego-Mendoza and Frisque, 2011). The β-TrCP1/2 binding 
motif is fully conserved in BKV and SA12. None of these interactions has been tested for the 
ability to affect transformation. 
I hypothesized that the JCV LT VHR does not have the same biological functions as 
SV40 LT VHR due to its sequence disparity, and that removal of the JCV VHR would allow it to 
transform cells to the same extent as SV40 LT. This chapter describes the effects on cellular 
transformation produced by removing the VHR from JCV and SV40 T antigens.  
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Figure 19. Structure and similarity of large T antigens. 
A) Structure of the large T antigen protein. Functional domains (rectangles) within large T are depicted. 
The functions and percent amino acid identity (gray bar) of each domain within SV40 and JCV large T 
are indicated above the diagram. At the N-terminus are the DNA J domain and linker region, which are 
both required to fully inhibit pRB activity. The origin binding domain is required for the viral genome 
replication. The zinc binding domain and the ATPase domain together contribute to the helicase activity 
of large T. Cellular p53 binds large T through surface residues of the ATPase domain. The variable linker 
region and host range region are poorly characterized in comparison to the other regions of large T 
antigen. B) VHR truncations of large T antigen. The variable linker and host range region was removed 
from each TAg gene. The VHR truncations express amino acids 1-625 of SV40 large T (SVN625) or 
amino acids 1-626 of JCV large T (JCN626). C) Protein sequence comparison of SV40 and JCV VHR 
regions. An alignment of amino acids was performed with LALIGN. The host range region of SV40 is 
highlighted in red letters, and was used to define the boundaries of the JCV host range region. Previously 
described motifs and post-translational modification sites are shown. 
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4.2 RESULTS 
4.2.1 Establishment of a system to compare the early regions of SV40 and JCV 
The full length (SV40.ER and JCV.ER) and VHR-truncated (SV40.ERΔVHR or JCV.ERΔVHR) 
early regions for both SV40 and JCV were cloned into the same expression vector. All four 
constructs were introduced into murine embryonic fibroblasts (MEFs), and pools of cells that 
survived selection were collected. We compared the ability of VHR truncated early regions to 
transform versus the full length counterparts. Three individual pools of cells were generated and 
tested for each construct to ensure that the observed phenotypes within an individual pool were 
not random.  
The early regions of both SV40 and JCV are capable of producing multiple protein 
products through alternative splicing mechanisms (Figure 20 A) (Trowbridge and Frisque, 1995; 
Zerrahn et al., 1993). Truncation of the JCV early region removes the 3’ splice acceptor sites for 
the T’165 and T’136 introns, ultimately preventing the corresponding proteins from being made. 
In addition, deletion of the VHR shortens the LT proteins to 625 and 626 aa in SV40 and JCV, 
respectively (Figure 19 B), causing a shift in apparent molecular size from ~94 to ~70 kD 
(Figure 20 B). Table 8 lists the expected protein products from each construct.  
  
 89 
 
  
 SV40.ER  SV40.ERΔVHR
Large T Large T (N625)
small T small T
17kT 17kT
 JCV.ER  JCV.ERΔVHR
Large T Large T (N626)
small T small T
T'165 T'135
T'136
T'135
 Expected Protein Products 
Potential protein products from both 
SV40.ER and SV40.ERΔVHR 
constructs are equivalent. Truncation of 
the VHR in JCV.ER removes two 3’ 
splice sites, which prevents expression 
of the T’165 and T’136 proteins.  
 
Table 8. Protein products potentially 
expressed from early region constructs. 
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Figure 20. Expression of T antigens from full length or VHR-truncated SV40 and JCV early region 
in MEFs.  
A) Transcripts and proteins encoded by the SV40 and JCV viral early region (ER). Both the SV40 and 
JCV ER produce multiple T antigen transcripts by alternative splicing (top panel). Translation of these 
transcripts results in a large T (LT), small T (sT), and one or more smaller T proteins (lower panel). Bars 
of the same color or pattern represent an expressed region of the protein within the same reading frame, 
while continuous lines represent regions that are removed due to alternative splicing of the early region 
pre-mRNA. Approximate sizes of the different T antigen proteins are listed. Removal of the VHR region 
in JCV prevents the expression of T’165 and T’136. Both SV40 and JCV VHR truncations produce a 
smaller LT protein. B) T antigen protein expression in MEFs from full length or VHR-truncated SV40 
and JCV ER. Three individual pools are shown (labeled A, B, and C) for each construct. Equivalent 
amounts of whole cell lysates were separated by SDS-PAGE, transferred to PVDF, and blotted for T 
antigens with a mixture of SV40 and JCV specific antibodies (materials and methods). GAPDH, loading 
control. C) T antigen transcripts amplified by RT-PCR using primers that surround the entire open 
reading frame (A and B or E and B, indicated by arrows in panel A). Each band corresponds to a different 
T antigen transcript: 1) SV40 sT, 2) SV40 LT, 3) SVN625, 4) JCV sT, 5) JCN626, 6) JCV T’165, 7) JCV 
T’136, 8) JCV T’135. D) RT-PCR specific for LT and sT transcripts (using primers C and D or F and G, 
indicated by arrows in panel A). Rpl5 was used as a cDNA loading control. 
LT 
sT and T’ 
proteins  
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4.2.2 Removal of the VHR alters the pattern of SV40 and JCV early region protein 
expression 
We first determined the protein and messenger RNA expression of T antigen products in each 
pool of cells by western blot and RT-PCR, respectively. In SV40.ER expressing cells LT was the 
dominant product identified at both the protein and mRNA levels (Figure 20 B, lanes 1-3; Figure 
20 C and D, SV40.ER lanes).  Small T protein was only detected after a long exposure (Figure 
20 B lanes 1-3), and the level of sT mRNA was lower than LT mRNA (Figure 20 D, SV40.ER 
lanes). LT protein expression was reduced when the VHR was removed from the SV40 early 
region, while sT protein expression increased (Figure 20 B lanes 4-6). The altered levels of LT 
and sT protein could not be attributed to changes in mRNA transcripts since there was no 
detectable difference in LT or sT transcripts between cell pools expressing SV40.ER and 
SV40.ERΔVHR (Figure 20 C and D, compare SV40.ER and SV40.ERΔVHR lanes). In 
preliminary experiments, we observed only a slight decrease in the half-life between full length 
and VHR truncated- LT protein (data not shown). This suggests that the stability of the protein 
was not significantly altered and should not account for the drastic decrease of SV40 LT protein 
in SV40.ERΔVHR cells.  
We were unable to detect the SV40 17kT protein. This is not surprising, since the level of 
17kT transcript was either extremely low or undetected in multiple experiments performed with 
all SV40-expressing pools (Figure 20 C and data not shown).  
 Unlike with SV40, LT was not the dominant protein seen in cells expressing the full 
length JCV early region. Rather, smaller T antigen proteins (sT, T’135, T’136, T’165) were 
expressed in the highest abundance (Figure 20 B, lanes 7-9), and this was reflected in the mRNA 
expression. The T’ transcripts were so abundant that we could not detect LT or sT transcripts 
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using a set of primers that amplify all T antigen transcripts (Figure 20 A, primers E and B; 
Figure 20 C, JCV ER lane). The inability to detect JCV LT and sT transcript was mostly likely 
because the T’ transcripts absorbed most of the primers during PCR amplification. To address 
this issue, a set of primers designed to amplify only LT, sT, or unspliced transcripts was used for 
RT-PCR (Figure 20 A, primers F and G), and both LT and sT transcripts were detected in the 
JCV.ER samples (Figure 20 D, JCV ER lanes). Removal of the VHR from JCV early region 
resulted in a decrease in LT protein (Figure 20 B, lanes 10-12) but, there was no significant 
change in the level of LT mRNA (Figure 20 D, compare JCV.ER to JCV.ERΔVHR lanes). 
Similar to JC.ER pools, the total level of smaller T antigens was higher than LT in 
JCV.ERΔVHR-expressing cells for both protein and mRNA (Figure 20 B, lanes 10-12; Figure 20 
C, JCV ERΔVHR lane). 
The identity of smaller T antigen proteins expressed from JCV.ER and JCV.ERΔVHR 
was difficult to discern by migration in SDS-PAGE. Instead, cDNA size analysis and sequencing 
revealed that JCV.ER pools expressed sT and all three T’ transcripts, while JCV.ERΔVHR pools 
produced only sT and T’135 transcripts due to the deletion (Figure 20 C,D and data not shown).  
Under our experimental conditions, the level of LT protein was similar between the SV40 and 
JCV ER-expressing cell pools (Figure 20 B, compare lanes 1-3 with lanes 7-9). However, 
expression of the VHR truncated JCV LT appeared to be higher than that observed for SV40 
LTΔVHR in the corresponding pools (Figure 20 B, compare lanes 4-6 with lanes 10-12), and the 
expression of both truncated LT proteins was comparatively reduced to that of their full length 
counterparts (Figure 20 B). 
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4.2.3 Growth in low serum conferred by SV40 is hindered by removal of the VHR  
MEFs respond to a reduction in serum levels in culture medium by ceasing proliferation and 
eventually dying (Figure 21 A,D and data not shown), but unrestricted growth in normal (10%) 
or low (1%) serum conditions takes place in the presence of some oncogenes, including SV40 
LT. All T antigen-expressing MEFs grew similarly in 10% serum (Figure 21 B,C,D), and the  
expression of either SV40.ER or JCV.ER allowed proliferation of MEFs at a similar rate in 1% 
serum (Figure 21 B,C,D). Truncation of the VHR from the JCV early region did not significantly 
alter the rate of cell growth in low serum (Figure 21 C,D). On the other hand, SV40.ERΔVHR 
was unable to allow cell growth in low serum. These cells doubled only once during the low 
serum treatment, similar to wild-type MEFs, whereas all other T antigen-expressing cells 
doubled at least twice while cultured in low serum for the same amount of time (Figure 21 B,C). 
Furthermore, the doubling time for the SV40.ERΔVHR MEFs was greater than that of all of the 
other T antigen-expressing cells (Figure 21 D). We did not find any difference in the level of 
large T antigen expressed in cells cultured in low serum compared to those in normal serum for 
either SV40.FL or SV40.ERΔVHR cells (data not shown).  
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Figure 21. SV40.ERΔVHR-expressing MEFs show limited growth in low serum. 
Cells were grown in medium containing either 10% or 1% serum for up to 12 days. Duplicate wells 
were counted at regular intervals and averaged. Two experiments performed with wild type MEFs are 
shown separately (A). For SV40 (B) and JCV samples (C), each point on the graph represents the 
average number of cells from 3 different cell pools expressing the same early region construct. Error 
bars denote the standard error of the mean. The doubling time was calculated from time points within 
the exponential phase of growth and the results are summarized in (D). Each value represents the 
average doubling time from 3 cell pools expressing the same early region construct. MEF values are 
the average of 2 independent experiments. The standard error of the mean is indicated. 
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4.2.4 Truncation of the JCV VHR region enhances anchorage independent 
transformation  
Both SV40 and JCV early regions have independently been shown to induce anchorage 
independent growth.  We analyzed the ability of full length and VHR-truncated viral early 
regions to induce this phenotype in MEFs. As expected, control MEF cells were unable to form a 
significant number of colonies when grown in agar suspension, but expression of all early region 
constructs resulted in formation of many colonies (Figure 22 A). In addition, the size of colonies 
formed in all early region expressing pools was significantly larger than colonies formed by 
control MEFs (Figure 22 B,C). 
We found that SV40.ER pools generated three times more colonies than JCV.ER pools 
(Figure 22 A), and also showed a higher frequency of extremely large outlier colonies (Figure 22 
B). However, the overall distribution of colony sizes was not significantly different between cells 
expressing these two constructs (Figure 22 C). This is consistent with previous reports using 
anchorage independence assays to compare SV40 and JCV T antigen transformation properties 
(Bollag et al., 1989; Hayashi et al., 2001; Trowbridge and Frisque, 1993).  
MEFs expressing the SV40 early region with or without the VHR showed similar 
numbers and sizes of anchorage independent colonies (Figure 22 A,B,C). On the other hand, 
removal of the VHR from JCV early region induced an increase in the number of colonies by 
more than 3 fold compared to cells expressing full length JCV early region (Figure 22 A). 
Furthermore, the size for JCV.ERΔVHR colonies was significantly larger than that observed for 
JCV.ER colonies (Figure 22 B,C,D). This was reflected in both an overall increase in the number 
of large-sized colonies and in the high frequency of extremely large outlier colonies found in 
JCV.ERΔVHR cell pools (Figure 22 B). 
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4.2.5 The VHR region is not required to interfere with the pRB pathway  
We assessed the ability of ERΔVHR products to perturb the pRB and p53 pathways, as both 
must be inhibited for full LT-mediated transformation to occur. Two markers were used to 
evaluate the integrity of the pRB pathway. First, western blot analysis was employed to assess 
the steady-state levels of the cellular protein p130, a member of the pRB family of proteins, 
which is reduced upon binding to SV40 LT (Lin and DeCaprio, 2003; Stubdal et al., 1997; 
Stubdal et al., 1996). Levels of p130 in all ER- and ERΔVHR-expressing MEFs were decreased 
compared to control MEFs (Figure 23 A). Next, we examined the expression levels of E2F target 
genes, which are increased as a downstream effect of LT inhibition of pRB proteins (Cantalupo 
et al., 2009). RT-PCR showed an increase in the level of transcript of a set of canonical E2F-
dependent genes in all cells expressing ER or ERΔVHR constructs when compared with non-
proliferating MEFs (Figure 23 B). These combined results suggest that the pRB pathway is 
effectively inhibited in all SV40 and JCV ER-expressing cells, irrespective of VHR truncation or 
level of LT produced.  
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Figure 23. Removal of the VHR does not alter the ability of T 
antigens to disrupt the pRB pathway. 
A) Steady state levels of p130 decrease in MEFs upon expression of 
either ER or ERΔVHR constructs, as monitored by Western blot. 
GAPDH was used as a loading control. B) E2F-target gene expression 
is increased in all T antigen-expressing MEFs. The expression of four 
E2F-regulated genes was assessed by RT-PCR of RNA from 2 days 
post-confluent cells. Pcna: proliferating cell nuclear antigen; Dhfr: 
dihydrofolate reductase; Mcm3: minichromosome maintenance 
complex component 3; Cdc6: cell division cycle 6. Rpl5 is an 
endogenous control. 
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4.2.6 p53 is bound and stabilized in all T antigen expressing MEFs  
Inactivation of the p53 pathway by LT is critical to induce most transformation phenotypes. One 
of the consequences of LT expression is the accumulation of p53 protein to very high levels in 
the cell. However, this p53 product is not functional, as LT binds the DNA binding domain of 
p53 and so prevents it from activating genes whose expression would lead to cell death (Jiang et 
al., 1993; Lilyestrom et al., 2006; Segawa et al., 1993). All ER- and ERΔVHR-expressing MEFs 
showed increased levels of p53 when compared to wild-type MEFs and MEFs treated with 
doxorubicin, a DNA damaging agent and inducer of p53 (Figure 24) (Attardi et al., 2004; 
Lorenzo et al., 2002). Although lower levels of total p53 were observed in cells expressing 
SV40.ERΔVHR when compared with SV40.ER pools, this decrease is consistent with the 
corresponding decrease in the amount of LT (Figure 24, compare lanes 3-5 with 6-8). In contrast, 
there was an increase in total p53 levels in JCV.ERΔVHR pools in comparison to JCV.ER pools, 
but in this case the LT expression levels remained similar or were slightly decreased when the 
VHR truncated LT was expressed (Figure 24, compare lanes 9-11 to 12-14). Despite the 
observed differences regarding total p53 levels attained in these cells, the ability of large T 
antigen to bind p53 – with or without the VHR – was conserved in both SV40 and JCV as shown 
by immunoprecipitation (Figure 25).   
In cells transformed by SV40 LT, the p53 protein bound by the large T antigen shows 
post-translational markers of activation (Borger and DeCaprio, 2006). We assessed the activation 
state of p53 in cells expressing the SV40 or JCV ER and ERΔVHR by examining K379-
acetylation and S15-phosphorylation by western blot. Control MEFs were treated with 
doxorubicin as a positive control for p53 activation. Doxorubicin-treated cells showed a 
significant increase in both post-translational modifications of p53 when compared to untreated 
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MEFs (Figure 24, compare lanes 1 and 2). SV40.ER pools produced the highest levels of 
acetylated and phosphorylated p53 (Figure 24, lanes 3-5). Similar to the total levels of p53, the 
amount of post-translationally modified p53 was decreased when the VHR was removed from 
SV40 (Figure 24, lanes 6-8). JCV.ER-expressing cells displayed a very low level of K379 
acetylation and S15 phosphorylation of p53 (Figure 24, lanes 9-11). Cells expressing the VHR 
truncated JCV early region showed increased levels of post-translationally modified p53 
compared to full length JCV early region pools (Figure 24, compare lanes 9-11 and 12-14), 
although these levels did not reach those observed in SV40.ER pools (Figure 24, compare lanes 
12-14 and 3-5). At present, it is unclear if variations in the p53 levels and modifications have a 
role in tumor induction by T antigens. 
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Figure 24. p53 is stabilized and shows different levels of activation in 
full length and VHR-truncated early region expressing MEFs. 
Steady-state levels of total and post-translationally modified p53 protein were 
detected by western blot in T antigen expressing cells. Large T-antigen levels 
are included for comparison. MEFs treated with doxorubicin were used as a 
positive control for p53 stabilization and activation. GAPDH, loading control.  
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Figure 25. VHR truncated large 
T antigens retain the ability to bind p53. 
Protein extracts were 
immunoprecipitated with a p53-
specific antibody (PAb 421,  SV40.ER 
and SV40.ERΔVHR samples) or a T 
antigen specific antibody (PAb 416, 
JCV.ER and JCV.ERΔVHR samples). 
Co-precipitated proteins were resolved 
by SDS-PAGE. The presence of large 
T and p53 was monitored by western 
blot. 
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4.3 DISCUSSION 
In order to explore contributions of the VHR to transformation, we examined the ability of SV40 
and JCV full length LT and LT mutants lacking the VHR to alter the growth properties of 
primary MEFs. We took advantage of the co-linearity of SV40 and JCV LT amino acid 
sequences to design VHR truncations that would not interfere with the structure of other LT 
domains. The full length and truncated early regions were cloned into the same vector and 
expressed from the CMV promoter. T antigen-expressing MEFs were then characterized for the 
ability to grow in low serum and to form anchorage independent colonies.  
Whereas normal MEFs proliferated slowly in 10% serum, were growth arrested in 1% 
serum, and could not form anchorage independent colonies, MEFs expressing the full length 
SV40 ER grew well at both serum concentrations and formed a significant number of AI 
colonies. Surprisingly, we found that cells expressing the SV40 VHR truncation failed to grow in 
1% serum, but showed no change in the ability to induce anchorage independent transformation. 
This was unexpected since the expression of SV.N136 in MEFs was sufficient to allow growth in 
low serum (Figure 14). This result indicates a new level of complexity of the synergy between 
the different domains of the SV40 LT protein in cell culture transformation.  
Some reports suggest that the degree of transformation by LT is dependent on the level of 
LT expression (Price et al., 1994; Sompayrac and Danna, 1992; Trowbridge and Frisque, 1993), 
and we observed a clear decrease in LT expression from the VHR-truncated SV40 ER, 
suggesting that this may contribute to the observed decrease of growth in low serum. This 
explanation is less likely, since anchorage independent growth was not affected. Another 
possibility is that a cellular protein that associates with the VHR region of SV40 LT contributes 
to the ability to grow in low serum. The variable region of SV40 LT shares little sequence 
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conservation with that of JCV, increasing the likelihood that a unique cellular protein could bind 
SV40 but not JCV in this region. 
Finally, the SV40 VHR mutant did not disrupt the interaction of LT with pRb proteins or 
binding to p53, which are required for LT to transform. However, it is possible that the VHR 
truncation alters the effect of LT on pRb or p53 in some way that our tests did not detect. One 
example could be that removal of the SV40 VHR disturbed CBP/p300 association with the LT-
p53 complex, resulting in the transformation defect seen here.  
In contrast to the SV40 VHR truncation, growth in low serum was not affected by 
removal of the JCV VHR region. Both mutant and full length JCV early regions grew at similar 
rates in 10% and 1% serum. Unexpectedly, VHR truncation of the JCV ER greatly enhanced the 
number and size of anchorage independent colonies compared to the full length JCV ER. JCV 
LT binding to the pRB and p53 proteins was not affected by removal of the VHR, indicating that 
the VHR mutant did not change one of these fundamental pathways required for transformation. 
Like SV40, LT expression decreased when JCV VHR was removed, but, unlike SV40, there was 
an increase of transformation, which challenges previous reports linking higher LT levels to 
increased transformation. However, due to the multiple T antigen proteins produced by the JCV 
early region constructs, it remains to be determined if the altered pattern of expression of JCV T 
antigens, the removal of the LT VHR region itself, or a combination of the two is responsible for 
the increased capacity to induce anchorage independent transformation.  
Another possible factor contributing to the altered transformation induced by the SV40 
and JCV truncated ERs is the level of p53 in the cells. For both truncated LTs, although the 
ability to bind p53 was not affected, the level of total, K379 acetylated, and S15 phosphorylated 
p53 changed depending on whether or not the VHR was present. The changes in total and 
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activated p53 levels correlated with the observed changes in transformation; growth in low 
serum was prevented and p53 levels were decreased when the VHR was deleted from the SV40 
early region, and removal of the VHR from JCV early region resulted in increased anchorage 
independent transformation and increased p53 levels. It is unclear how the level of p53 in the 
cells would contribute to the ability to transform if the interaction of LT with p53 only confers a 
loss of p53 function.  
Unfortunately, attempts to express either the SV40 or JCV VHR region alone or in 
combination with full length or truncated early regions in MEFs were not successful.  Also, 
efforts to express and test individual JCV T antigens were complicated by the limited life span of 
MEFs. As such, complementation studies or independent characterization of the JCV T antigen 
proteins or of the VHR alone were unable to be pursued. 
Further investigation of motifs within the VHR of both LTs was also hindered by 
unforeseen complications. The VHR region of SV40 has been shown to bind to the cellular 
protein Fbxw7, the specificity component of the SCF ubiquitin ligase complex, through a Cdc4 
phosphodegron motif between amino acids 699-705 anchored by threonine 701 (Welcker and 
Clurman, 2005). The full significance of this interaction is not known, but it is thought that SV40 
LT sequesters Fbxw7 from its normal cellular targets of degradation. Interestingly, JCV LT 
contains a partial Cdc4 phosphodegron motif, retaining the critical threonine residue and prolines 
at +1 and +2, but lacking a negatively charged residue at position +4 that was important for in 
vitro binding of SV40 LT to Fbxw7. Attempts to mutate the threonine to alanine or other 
residues resulted in a drastic change of splicing and protein expression for JCV ER (Figure 26 A 
and B); however, mutation of T701 to alanine did not significantly affect splicing or protein 
expression of SV40 ER (Figure 26 A and data not shown). The altered expression patterns in 
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cells expressing the JCV.ER point mutant could be due to the creation of a canonical splice 
acceptor site that does not occur with the same threonine point mutation in SV40 LT (Figure 26 
C).  
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Figure 26. Mutation of the threonine of the Fbw7 binding site within the JCV VHR alters 
splicing and protein expression of T antigens. 
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A) Transcripts from MEF pools expressing full length ER or a T to A mutation of the Fbw7 
binding site of JCV or SV40 constructs were reverse transcribed and amplified as described in 
Figure 18C. Predicted alternatively spliced mRNA species that correspond to the cDNA 
bands are depicted on the left. Transcripts for known T antigen products are designated.  
†, these mRNA species were verified by sequencing. *, due to limiting resolution, these JCV 
TAg bands could potentially include mRNA species with other 3’ splice acceptor sites; 
however, only the one shown has been verified by sequencing. B) The JCV ER, ERΔVHR, or 
ER.T684A constructs were expressed in MEFs and two monkey cell lines, BSC40 and CV1, 
and protein expression of T antigens was observed by Western blot. The top panel shows a 
blot performed with anti-SV40 antibody, 416, and the bottom panel was blotted with anti-JCV 
antibodies, 962 + 2003.  The location of LT is indicated. The proteins below 25 kD should 
include sT, T’165, T’ 136, and T’135 proteins; however the resolution of this gel was not 
good enough o say which band is which. Proteins located between 50 and 25 kD are unique 
JCV T antigen species that have not been previously described. These westerns were 
performed by M. T. Saenz Robles. C) The last 37 nt of JCV and 40 nt of SV40 normal and 
mutated ERs and were analyzed in the ESEfinder program to identify any change in exonic 
splicing enhancer binding sites introduced by the point mutation. The threonine codon is 
highlighted in bold, and the point mutation used to change the codon to alanine is in red. A 
cryptic 3’ splice acceptor site found in the JCV sequences is underlined. The point mutation in 
the JCV sequence introduces two new potential ESE binding sites and creates a common 
splice acceptor nt sequence AGG. The SV40 point mutation also adds more ESE binding 
sites, but no cryptic splicing acceptor sequences were found. ESE analysis was performed by 
Ping An. 
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A final perplexing result was the decrease in both SV40 and JCV LT protein expression 
when the VHR was removed. Why did these protein levels go down? LT mRNA analysis did not 
show a difference in LT transcript between full length and VHR truncations, indicating there was 
not a change in transcription of LT. I also performed preliminary experiments to determine if 
there was a decrease in protein stability when the VHR was removed (data not shown). 
Cyclohexamide chase showed no difference in half-life for JCV LT proteins, and only a slight 
decrease in half-life for SV40 LTΔVHR. These results did not convince me that stability was an 
issue. Several other mechanisms could regulate the level of protein including mRNA stability 
and shuttling out of the nucleus, frequency of translation of the LT transcript, or association to 
polysomes. These mechanisms will require further experimentation; however, at present, the 
results indicate that the VHR region is somehow linked to translation of the LT transcript.   
In summary, this is the first evidence linking the VHR region to transformation by any 
polyomavirus T antigen. Overall, our results indicate that the VHR from each virus early region 
confers different functional capabilities in terms of transformation, and that different 
transformation phenotypes are probably induced by distinct molecular mechanisms. Given these 
results, it is possible that VHR or C-terminal tail regions found in polyomaviruses other than 
SV40 may contribute to transformation in different ways than SV40 LT. 
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5.0  FUTURE DIRECTIONS AND PERSPECTIVES 
While we have learned much about polyomavirus T antigen induced transformation and 
tumorigenesis from the study of SV40 and MuPyV, the investigation of other PyVs has brought 
challenges to these established models. This thesis focused on two observations. The first 
unexplained observation is that BKV and JCV LTs do not transform with the same efficiency as 
SV40 LT, even though the amino acid sequences and mechanisms of transformation are highly 
similar. Second, the mechanisms of transformation of LPV are not well characterized and this 
has returned to the spotlight since the discovery of a very similar human virus, HuPyV 9. I took a 
structure-function approach to understand how individual domains of the LTs contribute to 
transformation by these viruses. Removal of specific domains of each LT revealed unique 
transformation properties for some polyomavirus proteins. Although fairly similar to SV40 in 
sequence, the short N-terminal fragments of BKV and JCV LT comprising the pRb binding 
domain and linker regions showed an additional transformation ability compared to an equivalent 
fragment for SV40 and LPV LTs. At the other end of the LT protein, removal of the variable 
linker and host range region from SV40 and JCV LTs induced changes in transformation by both 
proteins. These changes were opposing and specific to a particular assay. JCV LT VHR deletion 
allowed enhanced anchorage independent growth, while SV40 LT deletion prevented growth 
specifically in the low serum assay. The results from both studies highlighted many questions 
about the roles of individual T antigen proteins in transformation, the possibility of a p53 gain of 
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function activity when in complex with LT, and the ability of C-terminal tails to influence 
transformation potential. Below I discuss the future directions to address these questions. 
5.1 UNCOVERING THE MECHANISMS OF ENHANCED TRANSFORMATION BY 
DELETION OF THE VARIABLE REGION AND HOST RANGE REGION FROM JCV 
EARLY REGION 
While removal of the VHR region from both SV40 and JCV early regions resulted in interesting 
changes in transformation, the effects of truncation on the JCV early region should take priority 
in further studies for several reasons. First, JCV is a human virus that is directly involved in 
human disease and possibly cooperates in the development of some types of human cancer (as 
discussed in section 1.4). Thus, a better understanding of the regulation of transformation by 
JCV T antigens would directly benefit the human condition. Second, although truncations of 
JCV large T have not been observed in human samples, it is possible that a similar truncation 
could occur in an infected tissue and contribute to transformation. Third, one of the possible 
reasons for enhanced anchorage independence may lie in the altered expression of the JCV T’ 
proteins. Many other human polyomaviruses produce several T antigens while SV40 does not. 
Therefore, understanding the role of JCV T’ proteins in transformation may give insight into the 
other human polyomavirus T antigens. Finally, the more refined technique for assessing size and 
number of anchorage independent colonies developed in this work will allow further experiments 
to be monitored with precision, as compared to the low serum assay which is more susceptible to 
human error. Two possibilities should be experimentally explored to explain the enhanced 
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transformation capability of the VHR truncated JCV early region. These mechanisms are not 
mutually exclusive.  
First, there is the possibility that the removal of the VHR region from the JCV LT protein 
removes a binding site for a cellular protein that, when bound to JCV LT, dampens its ability to 
induce anchorage independent growth. A more refined and targeted mutation strategy within the 
VHR region tested in the anchorage independence assay could help to identify any cellular 
protein binding sites that enhance transformation.  
The VHR consists of two parts: the variable region and the host range region. The 
variable linker (variable in that this sequence differs the most between the four viruses that 
contain a VHR region) of JCV LT is 28 amino acids long and links the ATPase domain to the 35 
amino acid host range region (Figure 19 C). The host range region (HR) was initially identified 
in SV40 LT as required for virus to form plaques in CV-1 cells, but not in BSC or Vero cells 
(Tornow and Cole 1983, 1987). In addition, removal of the SV40 HR prevents a phenotype 
known as the adenovirus helper function (Tornow and Cole 1983). At least one known cellular 
protein, Fam111A, binds to full length SV40 LT through the HR, and is required to allow 
infection of certain cell types and to maintain the adenovirus helper function (Fine et al., 2012). 
The normal cellular function of Fam111A is currently unknown. The binding site is fairly 
conserved in JCV HR region, but has not been tested (Figure 19 C). Another protein known to 
bind specifically to the JCV LT VR is β-Transducin-repeat-containing protein 1/2 (Reviriego-
Mendoza and Frisque, 2011), which has not been tested for its potential to contribute to 
transformation by JCV LT.  
To understand if the binding of these proteins to the JCV LT VHR contributes to 
transformation they should be targeted for point mutation. Alanine or oppositely charged residue 
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substitutions of these sequences alone and in combination should be sufficient to reveal any 
effect on transformation. Since the Fam111A binding site is found in both SV40 and JCV HR 
regions, I expect that mutation of this site should not enhance transformation of MEFs by JCV 
LT. Conversely, as β-Transducin-repeat-containing protein 1/2 only interacts with JCV VR, this 
is a good candidate for potentially contributing to alteration of transformation. If there is no 
effect on transformation by mutation of these sequences, then a more general approach can be 
taken to isolate regions that, when deleted or mutated, enhance transformation. For instance, the 
HR or VR region alone can be deleted, or alanine scanning of the residues of each region may be 
performed. Alanine scanning should be performed with care so not to drastically change RNA 
signals in the T antigen mRNA that could complicate results (see section 4.3 Discussion).   
Second, the altered expression of JCV T antigen proteins could be responsible for the 
enhanced transformation of the JCV VHR truncation. The truncation was prevented from 
expressing T’165 and T’136, and the level of T’135 appeared to increase relative to the full 
length JCV early region (Figure 20 B and C). This could mean that T’165 and/or T’136 dampen 
the ability to transform cells to anchorage independent growth by JCV LT, or that T’135 
overexpression enhances transformation by JCV LT. There is one piece of evidence that mildly 
supports this hypothesis. In one previously published study from the Frisque group, each T’ 
protein was tested individually for its ability to cooperate with activated H-Ras to transform 
primary rat embryo fibroblasts (REFs) in a dense focus assay (Bollag et al., 2006). While all T’ 
proteins were able to cooperate with Ras, a test of immortalization of cells from several foci 
resulted in only half of the T’165 + Ras cell lines becoming immortal. In contrast, practically all 
of the T’135 and T’136 + Ras cell lines immortalized. This may suggest a potential inhibitory 
effect on transformation by T’165. Additionally, the authors felt that T’135 had the most robust 
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effect in the Ras cooperation assay since there was a consistently higher number of foci formed 
compared to the other T’ proteins. Unfortunately, a complete combinatorial analysis was not 
performed in this study.  
The effects on transformation when different combinations of JCV T antigens are 
expressed must be assessed. This includes the full length and VHR truncated JCV LT proteins 
expressed in combination with each T’ protein and sT. From a review of the JCV T antigen 
literature it is apparent that many studies use a JCV LT cDNA (which prevents sT expression but 
can still allow for T’ protein expression) without checking for T’ protein expression. Thus, a 
transcript that will only produce JCV LT must be created to gain a clear picture of how JCV LT 
behaves on its own in transformation studies. Of note, the Frisque group was successful in 
creating a LT only expression plasmid only after mutation of several cryptic splice sites that 
arose after mutation of known T’ splice sites; however, this construct was not tested in 
transformation assays (Prins and Frisque, 2001). Only with a LT only construct can the addition 
of T’ T antigens be properly evaluated for the effect on transformation. The most direct 
experiment would be to compare anchorage independent growth of cells expressing 
LT+sT+T’135 or LTΔVHR+sT+T’135 to determine if the presence of the VHR region has an 
effect when only these three JCV T antigens are present. 
The T’ proteins share the same first 132 amino acids with each other and JCV LT, 
differing only in a short tail at the C-terminus (Bollag et al., 2000). For T’135 and T’136 this 
short sequence contains three or four out of frame amino acids, respectively. The T’165 C-
terminal sequence, on the other hand, is the final 33 amino acids of JCV LT HR domain. Since 
the majority of the amino acid sequence of the three T’ proteins is identical any differences in 
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behavior would most likely be attributed to the different small C-terminal regions. These could 
easily be truncated or mutated to test this hypothesis. 
The testing of each of these potential mechanisms of transformation is likely to reveal 
many more questions to pursue to understand how the VHR of JCV T antigen and the 
combination of T antigen proteins affects transformation. Still, the knowledge gained from these 
studies in mouse embryo fibroblasts can be transferred to developing experiments in animal 
models of T antigen tumorigenesis or transformation of human cells, which would be more 
relevant to human disease. 
5.2 DEFINING THE ROLE OF THE LT-p53 COMPLEX IN T ANTIGEN INDUCED 
TRANSFORMATION 
One theme that arises from the work presented here is the relationship between LT and p53. 
Experiments with MEFs expressing the N-terminal fragments of SV40, BKV, and JCV LT in 
section 3.0 suggest that p53 interaction with LT is critical for robust dense focus formation and 
the ability to grow anchorage independent. In the presence of the N-terminal fragment, 
uninhibited p53 could become activated by stress signals in these environments and induce 
growth arrest. This would argue that the role of LT-p53 interaction is inhibition of the 
transactivating functions of p53. Indeed, as discussed in section 1.5.2, many studies have shown 
that binding of LT to p53 prevents the activation of its normal gene targets. 
On the other hand, the direct correlation between levels of p53 and transformation seen 
with the SV40 and JCV LT VHR truncations suggest that p53 could be acquiring a gain of 
function activity when in a complex with LT. It is possible that LT could redirect the activities of 
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bound, activated p53 to directly activate non-canonical genes. Another possibility is that LT uses 
p53 as a bridge for chromatin modifying enzymes, like CBP and p300, which would enhance 
transcription of genes required for transformation. Further experiments are needed to test this 
hypothesis, but at least two publications also support this idea. Deppert et al showed that SV40 
LT could not efficiently transform p53 knock out MEFs or cells that contained a p53 that had 
been mutated to remove the transactivation domain (Hermannstadter et al., 2009). Additionally, 
when p53 transactivation was impaired by expression of a dominant negative p53, SV40 LT 
mutants that could not bind p53 were not able to transform cells (Sachsenmeier and Pipas, 2001). 
This experiment argues that inhibition of p53-target gene expression is not the only element of 
LT-p53 binding required for transformation. 
Experiments to better understand if a gain-of-function exists will be complicated but 
should be pursued. The first thing that comes to mind is to remove p53 from a cell and see if the 
T antigens can still transform. Small interfering RNA treatment to remove or alter the levels of 
p53 in an already transformed cell would determine if the amount of LT-p53 complex influenced 
the transformation state. Studies with SV40 indicate that the p53 bound to LT is very stable; 
thus, the effect of siRNA knockdown might not be seen since this technique works at the level of 
translation. p53 might also be removed from the system by using cells from p53 -/- mice. When I 
put ER and ERΔVHR constructs of SV40 and JCV into p53 null MEFs (received from A. 
Levine), LT expression decreased dramatically complicating the fact that anchorage independent 
growth of the cells was also abolished (Figure 27 A and C).  
The binding of LT to p53 may stabilize not only p53 as was discussed before, but also 
LT. However, a preliminary treatment with MG132 did not show a change in LT protein 
expression, which argues against the loss of stability of LT when p53 is absent (Figure 27 B). 
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This further suggests that the absence of p53 affected LT expression at the level of transcription 
or translation.  How p53 could affect LT at these stages is not clear, and it is still possible that 
other protein degradation pathways are acting on LT when p53 cannot bind.  
Inversely, the LT-p53 complex could be prevented by mutating the p53 binding site with 
LT protein. This would ensure that only the interaction with p53 is prevented, as compared to the 
N-terminal fragments used in section 3.0 where any interactions with the C-terminus of LT that 
would contribute to transformation were removed. I mutated a critical aspartic acid (D) residue 
to asparagine (N) in SV40 and JCV ERΔVHR constructs to prevent LT-p53 binding (Figure 28). 
Unfortunately, the MEFs with the SV40 construct repeatedly did not survive drug selection after 
transduction, suggesting that the combination of the p53 binding mutation and removal of the 
VHR prevented LT immortalization. In contrast, I was able to create two selected pools of MEFs 
expressing JCV.ERΔVHR.D403N. Perhaps the many alternative T antigens expressed from the 
JCV ER as compared to the SV40 ER confer a growth advantage that prevents the lethality seen 
with the SV40 construct. As seen in the p53 null MEFs, JCV LT protein expression was greatly 
reduced in the JCV.ERΔVHR.D403N MEFs, again confusing the interpretation of the 
transformation results (Figure 28 A). Prevention of p53 binding to JCV LTΔVHR greatly 
reduced transformation (Figure 28 B). In both experiments where the LT-p53 complex was 
prevented, the LT protein levels and transformation decreased. 
At least two questions arise from these observations which will need to be further 
investigated. First, it still remains unclear as to whether active p53 is required to bind to LT to 
induce transformation since the severe reduction in LT levels in p53 null MEFs may have been 
below the threshold required to transform cells. In this case, it would be interesting to introduce 
and compare mutants of p53 that prevent promoter transactivation, mutants that inhibit binding 
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of p53 to specific chromatin modifying proteins, or wild type p53 into the p53 null MEFs with T 
antigen. These cells could then be compared in transformation assays and to see if binding of a 
“dead” p53 would rescue levels of LT. Second, why do both SV40 and JCV LT levels drop when 
p53 cannot bind to LT? As mentioned before, p53 interaction might be preventing the 
degradation of the LT protein by non-proteasome dependent pathways. There is evidence that 
some cellular protein levels are maintained through autophagy (reviewed in Cuervo and Wong, 
2014), which supports this theory.  
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Figure 27. LT expression and transformation are reduced in p53 null MEFs. 
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The SV49 and JCV ER and ERΔVHR constructs were expressed in p53 -/- MEFs and 
compared to the MEF p53 +/+ SV40 and JCV ER pools described in section 3.0. A) Protein 
expression of T antigens by Western blot. All lanes are from the same blot, but some lanes 
were removed for clarity. A mixture of SV40 and JCV antibodies was used to detect the T 
antigens. Note the decrease in LT expression for both SV40 and JCV constructs when p53 
is absent. The levels of the smaller T antigens in the JCV.ER cells do not change regardless 
of p53 expression. B) Inhibition of the proteasome by MG132 treatment does not 
significantly change LT levels in p53 -/- MEFs. MG132 was dissolved in DMSO and added 
to cell culture medium at a concentration of 10 or 20 μM. Negative controls received the 
same amount of DMSO without MG132. After a short incubation, cells were collected and 
LT expression was observed by Western blot. The same procedure was performed on p53 
+/+ MEFs with no T antigen to determine if the concentrations of MG132 used were 
effective. p53 was monitored in these cells since it is known to have a very short half-life 
and be degraded by the proteasome. These experiments were performed by Memphis Hill. 
C) Anchorage independent (AI) colonies formed in a preliminary soft agar assay. MEFs 
with (+/+) or without (-/-) p53 did not form a significant number of colonies without T 
antigen. AI growth was essentially abolished in cells expressing SV40 or JCV ER, but 
lacking p53.    
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Figure 28. The D403N mutation prevents p53 binding to JCV LTΔVHR and reduces its 
ability to induce anchorage independent growth.  
A point mutant was introduced into the ATPase domain of the JCV.ERΔVHR construct to prevent 
binding of p53 to LT ΔVHR (D403N). A) Protein expression analysis by Western blot showed a 
decrease in LT expression of the D403N mutant compared to the unaltered JCV.ERΔVHR 
expressing MEFs. p53 was undetected in the D403N samples, suggesting that p53 was not binding 
to the LT as expected. B) Both unaltered (D403) and mutated (D403N) JCV.ERΔVHR were tested 
for the ability to induce anchorage independent growth in MEFS. Each image in a row is from the 
same field of view of a soft agar plate, but each is focused at a different depth of the agar layer. 
Black arrows indicate unique AI colonies. It is clear that the lack of p53 binding to LT has reduced 
both the number and size of AI colonies.  
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5.3 HOW DO ALTERNATIVE T ANTIGENS OF OTHER POLYOMAVIRUSES 
AFFECT TRANSFORMATION?  
Several of the newly discovered human polyomaviruses produce T antigens in addition to LT 
and sT. While SV40 also produces an alternative T antigen, 17kT, it was shown not to be 
important for transformation, and so interest in the alternative T antigens fizzled out. The work 
presented in this thesis points to potential roles at least for JCV, but also possibly for BKV, in 
transformation.    
JCV early region produces three proteins, T’135, T’136, and T’165, in addition to LT and 
sT. All three proteins contain a J domain, N-terminal linker, and a small tail that is either in 
frame with the JCV LT VHR region (T’165) or out of frame (T’135, T’136). This makes these 
proteins similar to the JCV N137 fragment used in Chapter 3. Congruent with the JCV N137 
effect on p130, all three T’ proteins have been shown to bind pRB; however, they may bind to 
pRB, p107, and p130 with different affinities (Bollag et al., 2000). Previous work has shown that 
the T’ proteins have some transformation potential when expressed alone – including growth in 
low serum and cooperation with activated Ras to form dense foci (Bollag et al., 2006), which is 
similar to what was seen with JCV N137 fragment. Moreover, when only the LT was expressed 
(because all splice sites for T’ proteins and small T were mutated) only 1 clone out of 30 
survived the selection process and LT expression was low (Bollag et al., 2006), suggesting these 
proteins grant an advantage when expressed with LT. Other work presented in Chapter 4 
suggests that T’165, whose C-terminal tail is part of the JCV VHR region, may confer a negative 
effect on transformation. In fact, one possibility for the increase in transformation seen when the 
JCV VHR was removed could be that expression of T’165 and T’136 was prevented, leaving 
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only LTΔVHR, sT, and T’135. The combination of T’ proteins, LT, and sT may be an important 
factor in JCV early region induced transformation.   
Human Merkel Cell PyV, BKV, and STLPyV also produce T antigen proteins besides LT 
and sT. BKV produces one additional T antigen protein, called mini T (Abend et al., 2009), and 
it’s sequence closely resembles JCV T’135 or T’136. STLPyV and MCPyV “other” T antigens 
appear to be unique in sequence and could therefore also have unique functions in transformation 
as well as viral replication. STLPyV also creates one additional T antigen protein, 229T, that 
contains the entire sT coding region with an additional 38 amino acids that are not in frame with 
the LT (Lim et al., 2013). PyV small T antigens are important transforming proteins and an 
added 38 a.a. may allow for additional cellular proteins to bind that have not been seen before for 
other sT proteins. Most fascinating is MCPyV, which makes 57kT and ALTO T antigens in 
addition to LT and sT. 57kT is similar to JCV T’ in that it contains the J domain and N-terminal 
linker of LT; however, 57kT also codes for a portion of the OBD and the last 100 a.a. of the 
MCPyV LT (Spurgeon and Lambert, 2013). This last 100 a.a. includes part of the helicase 
domain and a 26 a.a. C-terminal tail which may be akin to the VR region of JCV LT. Another 
interesting observation is that in Merkel cell tumors MCPyV LT is frequently truncated to 
remove the helicase domain and C-terminal tail, and therefore the 57kT product (Borchert et al., 
2014). 57kT could potentially have a negative effect on transformation alone or when in 
combination with other MCPyV T antigens, similar to that hypothesized for JCV T’165. In fact, 
57kT imparted a growth inhibitory effect to cells when expressed independently compared to full 
length LT or a truncated LT (Cheng et al., 2013). The mechanisms of action for these 
observations remain to be uncovered. Finally, MCPyV ALTO protein is the first T antigen of its 
kind (Carter et al., 2013). ALTO is transcribed from an alternative start site within the early 
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region. The protein spans the entire N-terminal linker region but is frame-shifted so that the 
protein sequence is entire different from the other T antigens. So far no biological function has 
been assigned to the ALTO protein, but it was shown to be expressed during, but not required 
for, MCPyV DNA replication, pointing to a possible role in reprogramming of the cellular 
environment.  
Taken together, the hypothesis put forth for JCV T’ proteins and the published work 
discussed here suggest that “other” T antigens from human PyVs have the potential to have both 
positive and negative contributions to transformation. Therefore, more careful consideration of 
these alternative T antigens is needed in transformation and tumorigenesis studies.    
5.4 C-TERMINAL TAILS OF LARGE T ANTIGENS ARE LIKELY TO HAVE A 
MORE SIGNIFICANT ROLE IN POLYOMAVIRUS BIOLOGY 
The identification of the variable linker and host range region as a 4th region of large T 
antigen to contribute to transformation prompted a closer look at sequences following the 
ATPase domains of other T antigens (termed C-terminal tails). The goal was to identify any 
conserved regions or motifs. Conserved regions would likely be important for some aspect of 
polyomavirus biology, and, therefore, mutation of these regions would provide the best chance to 
observe a phenotype. It should be noted that not all PyV LT proteins have a C-terminal tail.  
I analyzed LT sequences with C-terminal tails from 48 different polyomaviruses over a 
range of host-specificities. For clarity of alignments, I removed the HR-specific portions from 
SV40, BKV, JCV, and SA12, leaving just the VR region. (As a side note, these are the only LTs 
that contain an HR-like sequence). Sometimes there were subgroups within polyomaviruses that 
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infect the same type of host (primate and humans), whereas others showed no identifiable 
similarities in the C-terminal tails (bats and birds); however, grouping the sequences by similar 
host species did not reveal anything unique. As a whole, the C-terminal tails fell into two major 
groups, those that began with proline-leucine (PL) or isoleucine-leucine (IL) amino acids (Figure 
29 A and B). A third group was made up of all non-PL/IL sequences (Figure 29 C). A few 
common themes were found associated with each group. 
The majority of “PL” group sequences contained a motif at the N-terminus, P L x x I/LV 
I/L/V. This motif is often followed by a high density of negatively charged amino acids. A 
search for other viral or cellular proteins that contain a similar motif was so varied that no 
significance could be seen. However, the conservation of this motif in so many C-terminal tails 
makes it a candidate for mutation and further testing. About half of the PyV “PL” sequences also 
contained a partially conserved motif at the C-terminal end that begins with DSG followed by 
some combination of F, Q, and T. 
“IL” group C-terminal tails were correlated with higher serine (S) and glutamine (Q) 
content. Three sequences of the “IL” group also contained high proline content. I could not find 
any information about SQ repeats or content within known proteins; however, there is a gene 
found in humans and animals called glutamine serine rich 1 (QSER1). Microarray analysis found 
expression of QSER1 to be significantly increased in livers from patients with recurrent HCV 
hepatic tumors (Das et al., 2013). Additionally, QSER1 protein was found associated with 
mitotic RNA polymerase II in a proteomic analysis of this complex (Moller et al., 2012). 
Although it is hard to draw links between QSER1 and the SQ content of the PyV C-terminal 
tails, the information about QSER1 suggests that this grouping of amino acids has an important 
biological function that PyVs could be mimicking. Finally, DSG-beginning motifs were also 
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found in this group; however, the motif was followed by different amino acids from those of the 
“PL” group. The DSGHGSS motif, shown to bind to cellular protein β-TRCP 1/2 in JCV LT, 
was conserved in SA12 and BKV. An alternate motif, D-S-G-hydrophobic-x-S, was found in 3 
sequences in this group. 
There were a few outlier C-terminal tails that did not begin with “PL” or “IL”. These 
sequences did not share significant homology with each other, but I did identify degenerate DSG 
motifs in three out of five. HuPyV 6 and 7 had an identical motif, E-S-G-I-G-S, while California 
sea lion PyV contained the D-S-G-hydrophobic-x-S motif seen in the “IL” group.  
Research into DSG motifs revealed that they are commonly found in human proteins as 
“phosphodegrons” (Jiang et al., 2011; Lau et al., 2014). Phosphodegrons are motifs containing 
either a phosphorylated serine or threonine residue, which is bound by the substrate-specificity 
component of the ubiquitin ligase complexes. The phosphorylated phosphodegron therefore 
marks a protein for ubiquitination, and ultimately degradation. There are 69 putative Fbox 
proteins in humans, and at least three have been shown to be mutated or overexpressed in some 
cancers (Lau et al., 2014). Interestingly, two Fbox proteins are already known to bind PyV LT 
proteins in the C-terminal tails: JCV binds β-TRCP 1/2 (aka Fbxw-1 and Fbxw-11) (Reviriego-
Mendoza and Frisque, 2011), and SV40 binds Fbxw7 (Welcker and Clurman, 2005). Neither of 
these interactions targets the LT for ubiquitination, favoring a sequestration model, although the 
effect of sequestration is not understood. 
Clearly, C-terminal tails of PyV LTs play a significant role in the biology of some of 
these viruses. The conservation of DSG phophodegron-like motifs across PyV species suggests 
an important function for Fbox protein binding in the life cycle of these PyVs. Moreover, the 
identification of subgroups of conserved motifs and patterns of amino acids indicates that some 
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PyVs have gained additional, important functions in this region. The biological role of these 
conserved regions remains to be seen, but promises to unlock a whole new arm of cellular and 
polyomavirus-related biology. 
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